Ignite Creation Date:
2025-12-25 @ 12:43 AM
Ignite Modification Date:
2025-12-25 @ 10:54 PM
Study NCT ID:
NCT01641367
Status:
COMPLETED
Last Update Posted:
2019-03-15
First Post:
2012-06-28
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D000069454', 'term': 'Darunavir'}, {'id': 'C451734', 'term': 'etravirine'}, {'id': 'D000069480', 'term': 'Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination'}, {'id': 'D000068898', 'term': 'Raltegravir Potassium'}, {'id': 'C021623', 'term': 'bactericidal permeability increasing protein'}, {'id': 'D019438', 'term': 'Ritonavir'}], 'ancestors': [{'id': 'D013449', 'term': 'Sulfonamides'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D002219', 'term': 'Carbamates'}, {'id': 'D000144', 'term': 'Acids, Acyclic'}, {'id': 'D002264', 'term': 'Carboxylic Acids'}, {'id': 'D013450', 'term': 'Sulfones'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}, {'id': 'D005663', 'term': 'Furans'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D000068698', 'term': 'Tenofovir'}, {'id': 'D063065', 'term': 'Organophosphonates'}, {'id': 'D009943', 'term': 'Organophosphorus Compounds'}, {'id': 'D000068679', 'term': 'Emtricitabine'}, {'id': 'D003841', 'term': 'Deoxycytidine'}, {'id': 'D003562', 'term': 'Cytidine'}, {'id': 'D011741', 'term': 'Pyrimidine Nucleosides'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D000225', 'term': 'Adenine'}, {'id': 'D011687', 'term': 'Purines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D003853', 'term': 'Deoxyribonucleosides'}, {'id': 'D009705', 'term': 'Nucleosides'}, {'id': 'D009706', 'term': 'Nucleic Acids, Nucleotides, and Nucleosides'}, {'id': 'D004338', 'term': 'Drug Combinations'}, {'id': 'D004364', 'term': 'Pharmaceutical Preparations'}, {'id': 'D011760', 'term': 'Pyrrolidinones'}, {'id': 'D011759', 'term': 'Pyrrolidines'}, {'id': 'D013844', 'term': 'Thiazoles'}, {'id': 'D001393', 'term': 'Azoles'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ACTGCT.Gov@s-3.com', 'phone': '(301) 628-3313', 'title': 'ACTG Clinicaltrials.gov Coordinator', 'organization': 'ACTG Network Coordinating Center, Social and Scientific Systems, Inc.'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': 'From enrollment to the end of step 1/2 follow up. Participants were followed in Steps 1 and 2 until 48 weeks after the last participant was enrolled to Step 1. Median follow-up time was 72 weeks, maximum of 204 weeks.', 'description': 'Version 2.0 of the DAIDS EAE Manual was used for this study. At entry, signs, symptoms and laboratory values regardless of grade that occurred \\<30 days before entry were reported. Post-entry, signs/symptoms and laboratory values grade ≥3, or caused a change in treatment/ART regardless of grade, were reported. Diagnoses identified on the study-specific list, or caused a change in treatment, were recorded at all visits. Used DAIDS AE Grading Table, Version 1.0, December 2004 (clarified AUG09)', 'eventGroups': [{'id': 'EG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.', 'otherNumAtRisk': 287, 'deathsNumAtRisk': 287, 'otherNumAffected': 283, 'seriousNumAtRisk': 287, 'deathsNumAffected': 18, 'seriousNumAffected': 61}, {'id': 'EG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV', 'otherNumAtRisk': 74, 'deathsNumAtRisk': 74, 'otherNumAffected': 72, 'seriousNumAtRisk': 74, 'deathsNumAffected': 1, 'seriousNumAffected': 8}, {'id': 'EG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV', 'otherNumAtRisk': 72, 'deathsNumAtRisk': 72, 'otherNumAffected': 69, 'seriousNumAtRisk': 72, 'deathsNumAffected': 2, 'seriousNumAffected': 13}, {'id': 'EG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC', 'otherNumAtRisk': 8, 'deathsNumAtRisk': 8, 'otherNumAffected': 8, 'seriousNumAtRisk': 8, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV', 'otherNumAtRisk': 70, 'deathsNumAtRisk': 70, 'otherNumAffected': 69, 'seriousNumAtRisk': 70, 'deathsNumAffected': 1, 'seriousNumAffected': 9}, {'id': 'EG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs', 'otherNumAtRisk': 34, 'deathsNumAtRisk': 34, 'otherNumAffected': 33, 'seriousNumAtRisk': 34, 'deathsNumAffected': 1, 'seriousNumAffected': 6}], 'otherEvents': [{'term': 'Conjunctivitis allergic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Eye pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 18}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Abdominal pain upper', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Abdominal tenderness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 22}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 7}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Peptic ulcer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 23}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Chills', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Oedema peripheral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 53}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 8}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 8}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 8}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 9}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Hepatitis acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Acarodermatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Acute sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Bacteraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Bacterial vaginosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Body tinea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Chronic hepatitis B', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Conjunctivitis bacterial', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Helminthic infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Herpes zoster', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 4}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Influenza', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Oral candidiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 19}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Pneumonia bacterial', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Purulent discharge', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 19}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 7}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 6}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 15}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Vulvovaginal candidiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Alanine aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 41}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 12}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 11}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 6}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Aspartate aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 68}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 14}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 13}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 18}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 8}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Blood alkaline phosphatase abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Blood alkaline phosphatase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 68}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 20}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 16}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 26}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 7}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Blood bicarbonate decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 94}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 22}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 23}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 27}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 14}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Blood bilirubin increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 106}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 19}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 12}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 22}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 6}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Blood cholesterol increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 65}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 41}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 40}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 31}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 16}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Blood creatinine increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 37}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 10}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 8}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 9}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 4}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Blood glucose decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 32}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 10}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 7}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Blood glucose increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 72}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 15}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 22}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 21}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 11}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Blood phosphorus decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 75}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 25}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 21}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 20}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 12}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Blood potassium decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 34}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 12}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 4}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 5}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Blood potassium increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 14}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 5}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Blood pressure increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Blood sodium decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 145}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 44}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 32}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 8}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 42}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 16}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Blood sodium increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 42}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 7}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 4}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Blood triglycerides increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Haemoglobin decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 40}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 8}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 9}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 6}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 7}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Low density lipoprotein increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 65}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 42}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 37}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 32}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 16}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Neutrophil count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 64}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 21}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 20}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 15}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 9}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Platelet count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 23}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 8}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Weight decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 25}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'White blood cell count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 22}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 11}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 7}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 5}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Decreased appetite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 17}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 3}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Costochondritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Pain in extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 3}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 27}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 10}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 3}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Neuropathy peripheral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Paraesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Seizure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Dysuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 13}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Pollakiuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Urine odour abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Cervical dysplasia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Vaginal discharge', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 3}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Vulvovaginal pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 50}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 14}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 9}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 8}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Dyspnoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 14}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Nasal congestion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 5}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Oropharyngeal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Oropharyngeal plaque', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 17}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Rhinorrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 18}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 8}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 5}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Sinus pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Blister', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Erythema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Rash', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Rash generalised', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 2}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Skin lesion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 4}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Urticaria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 3}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}], 'seriousEvents': [{'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Anaemia megaloblastic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Leukopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Lymphopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Acute myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Ulcerative keratitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Gastrointestinal disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Death', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Systemic inflammatory response syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Hepatitis acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Hepatotoxicity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Immunosuppression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Immune system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Amoebiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Appendicitis perforated', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Atypical pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Bacteraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Cerebral toxoplasmosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Dengue fever', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Disseminated tuberculosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Encephalitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'HIV-associated neurocognitive disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Herpes zoster', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Leptospirosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Lower respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Malaria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Mastoiditis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Meningitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Meningitis bacterial', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Meningitis cryptococcal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Meningitis pneumococcal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Neurocryptococcosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Oesophageal candidiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Otitis media acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Peritonitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Pneumocystis jirovecii pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Pneumonia bacterial', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Pneumonia haemophilus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Pulmonary tuberculosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Pyelonephritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Scrub typhus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Sepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Septic shock', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Wound infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Ankle fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Hand fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Tibia fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Traumatic fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Upper limb fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Blood alkaline phosphatase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Weight decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'White blood cell count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Cachexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Dehydration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Electrolyte imbalance', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Hypercholesterolaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Hyperglycaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Hypophosphataemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Osteonecrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Cervix carcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Myelodysplastic syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Oesophageal carcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Prostate cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Dystonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Facial paralysis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Seizure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Syncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Tension headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Abortion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Pregnancy, puerperium and perinatal conditions', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Abortion threatened', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Pregnancy, puerperium and perinatal conditions', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Foetal hypokinesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Pregnancy, puerperium and perinatal conditions', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Pregnancy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Pregnancy, puerperium and perinatal conditions', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Stillbirth', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Pregnancy, puerperium and perinatal conditions', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Glomerulonephritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Renal failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Renal impairment', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Idiopathic interstitial pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Respiratory failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Angioedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Hypovolaemic shock', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Jugular vein thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Pelvic venous thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 287, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 72, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 34, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 48 Weeks', 'denoms': [{'units': 'Participants', 'counts': [{'value': '545', 'groupId': 'OG000'}, {'value': '287', 'groupId': 'OG001'}, {'value': '74', 'groupId': 'OG002'}, {'value': '72', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '70', 'groupId': 'OG005'}, {'value': '34', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Overall Study', 'description': 'Entire enrolled population spanning all arms and interventions.'}, {'id': 'OG001', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG004', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG005', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG006', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'categories': [{'measurements': [{'value': '0.64', 'groupId': 'OG000', 'lowerLimit': '0.60', 'upperLimit': '0.68'}, {'value': '0.44', 'groupId': 'OG001', 'lowerLimit': '0.38', 'upperLimit': '0.49'}, {'value': '0.88', 'groupId': 'OG002', 'lowerLimit': '0.80', 'upperLimit': '0.95'}, {'value': '0.88', 'groupId': 'OG003', 'lowerLimit': '0.80', 'upperLimit': '0.95'}, {'value': '1.00', 'groupId': 'OG004', 'lowerLimit': '0.63', 'upperLimit': '1.00'}, {'value': '0.90', 'groupId': 'OG005', 'lowerLimit': '0.83', 'upperLimit': '0.97'}, {'value': '0.74', 'groupId': 'OG006', 'lowerLimit': '0.59', 'upperLimit': '0.88'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '48 weeks after the date of entry', 'description': 'The measurement closest to exactly 48 weeks (ie, 7x48=336 days) after the date of entry, within the window of 48 weeks ± 6 weeks (specifically 295 to 378 days after randomization, inclusive).\n\nThe analysis in the protocol and in the Stat. Analysis Plan involved estimating the proportion of participants in the overall study population with HIV-1 RNA ≤200 copies/mL at week 48 with a 95% confidence interval calculated via a Wald approach. Death or lost to follow-up before week 48 was considered as HIV-1 RNA\\>200 copies/mL at week 48. Missing results at week 48 were considered as HIV-1 RNA \\>200 copies/mL at week 48 unless the immediately preceding and succeeding HIV-1 RNA measurements were ≤200 copies/mL. Since the primary analysis was on the total study population, overall results were also submitted. All participants in B3 had HIV-1 RNA ≤200 copies/mL at week 48. Therefore, Wald confidence interval could not be computed for B3 and Clopper-Pearson Exact confidence interval is provided.', 'unitOfMeasure': 'proportion of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All enrolled participants'}, {'type': 'SECONDARY', 'title': 'Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 24 Weeks', 'denoms': [{'units': 'Participants', 'counts': [{'value': '545', 'groupId': 'OG000'}, {'value': '287', 'groupId': 'OG001'}, {'value': '74', 'groupId': 'OG002'}, {'value': '72', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '70', 'groupId': 'OG005'}, {'value': '34', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Overall Study', 'description': 'Entire enrolled population spanning all arms and interventions.'}, {'id': 'OG001', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG004', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG005', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG006', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'categories': [{'measurements': [{'value': '0.64', 'groupId': 'OG000', 'lowerLimit': '0.60', 'upperLimit': '0.68'}, {'value': '0.43', 'groupId': 'OG001', 'lowerLimit': '0.37', 'upperLimit': '0.48'}, {'value': '0.89', 'groupId': 'OG002', 'lowerLimit': '0.82', 'upperLimit': '0.96'}, {'value': '0.88', 'groupId': 'OG003', 'lowerLimit': '0.80', 'upperLimit': '0.95'}, {'value': '1.00', 'groupId': 'OG004', 'lowerLimit': '0.63', 'upperLimit': '1.00'}, {'value': '0.90', 'groupId': 'OG005', 'lowerLimit': '0.83', 'upperLimit': '0.97'}, {'value': '0.74', 'groupId': 'OG006', 'lowerLimit': '0.59', 'upperLimit': '0.88'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '24 weeks after the date of entry', 'description': 'The measurement closest to exactly 24 weeks (ie, 7x24=168 days) after the date of entry, within the window of 24 weeks ± 6 weeks (specifically 127 to 210 days after randomization, inclusive).\n\nThe analysis in the protocol and in the Stat. Analysis Plan involved estimating the proportion of participants in the overall study population with HIV-1 RNA ≤200 copies/mL at week 24 with a 95% confidence interval calculated via a Wald approach. Death or lost to follow-up before week 24 was considered as HIV-1 RNA\\>200 copies/mL at week 24. Missing results at week 24 were considered as HIV-1 RNA \\>200 copies/mL at week 24 unless the immediately preceding and succeeding HIV-1 RNA measurements were ≤200 copies/mL. Since the primary analysis was on the total study population, overall results were also submitted. All participants in B3 had HIV-1 RNA ≤200 copies/mL at week 24. Therefore, Wald confidence interval could not be computed for B3 and Clopper-Pearson Exact confidence interval is provided.', 'unitOfMeasure': 'proportion of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All enrolled participants'}, {'type': 'SECONDARY', 'title': 'Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 72 Weeks', 'denoms': [{'units': 'Participants', 'counts': [{'value': '448', 'groupId': 'OG000'}, {'value': '234', 'groupId': 'OG001'}, {'value': '61', 'groupId': 'OG002'}, {'value': '62', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '54', 'groupId': 'OG005'}, {'value': '31', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'Overall Study', 'description': 'Entire enrolled population spanning all arms and interventions.'}, {'id': 'OG001', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG004', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG005', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG006', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'categories': [{'measurements': [{'value': '0.64', 'groupId': 'OG000', 'lowerLimit': '0.60', 'upperLimit': '0.69'}, {'value': '0.44', 'groupId': 'OG001', 'lowerLimit': '0.37', 'upperLimit': '0.50'}, {'value': '0.92', 'groupId': 'OG002', 'lowerLimit': '0.85', 'upperLimit': '0.99'}, {'value': '0.87', 'groupId': 'OG003', 'lowerLimit': '0.79', 'upperLimit': '0.95'}, {'value': '1.00', 'groupId': 'OG004', 'lowerLimit': '0.54', 'upperLimit': '1.00'}, {'value': '0.85', 'groupId': 'OG005', 'lowerLimit': '0.76', 'upperLimit': '0.95'}, {'value': '0.77', 'groupId': 'OG006', 'lowerLimit': '0.63', 'upperLimit': '0.92'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '72 weeks after the date of entry', 'description': 'The measurement closest to exactly 72 weeks (ie, 7x72=504 days) after the date of entry, within the window of 72 weeks ± 6 weeks (specifically 463 to 546 days, inclusive).\n\nThe analysis in the protocol and in the Analysis Plan involved estimating the proportion of participants in the overall study population with HIV-1 RNA ≤200 copies/mL at week 72 with a 95% confidence interval calculated via a Wald approach. Death or lost to follow-up before week 72 was considered as HIV-1 RNA\\>200 copies/mL at week 72. If a result was expected, missing results at week 72 were considered as HIV-1 RNA \\>200 copies/mL at week 72 unless the immediately preceding and succeeding HIV-1 RNA measurements were ≤200 copies/mL. Since the primary analysis was on the total study population, overall results were also submitted. All participants in B3 had HIV-1 RNA ≤200 copies/mL at week 72. Therefore, Wald confidence interval could not be computed for B3 and Clopper-Pearson Exact confidence interval is provided.', 'unitOfMeasure': 'proportion of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants with results expected at week 72'}, {'type': 'SECONDARY', 'title': 'Number of Weeks of Follow-up', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'categories': [{'measurements': [{'value': '72', 'groupId': 'OG000', 'lowerLimit': '60', 'upperLimit': '96'}, {'value': '96', 'groupId': 'OG001', 'lowerLimit': '72', 'upperLimit': '132'}, {'value': '84', 'groupId': 'OG002', 'lowerLimit': '72', 'upperLimit': '126'}, {'value': '96', 'groupId': 'OG003', 'lowerLimit': '66', 'upperLimit': '120'}, {'value': '72', 'groupId': 'OG004', 'lowerLimit': '60', 'upperLimit': '96'}, {'value': '96', 'groupId': 'OG005', 'lowerLimit': '84', 'upperLimit': '144'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'From study entry through Step 1/2 follow-up', 'description': 'All participants were followed on step 1/2 until 48 weeks after the last participant was enrolled to step 1 regardless of virologic status or treatment switches. Length of follow-up varied by Cohort.', 'unitOfMeasure': 'weeks', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED', 'populationDescription': 'all enrolled participants'}, {'type': 'SECONDARY', 'title': 'Time to Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'title': '1st percentile', 'categories': [{'measurements': [{'value': '24', 'groupId': 'OG000', 'lowerLimit': '24', 'upperLimit': '24'}, {'value': '24', 'groupId': 'OG001', 'lowerLimit': '24', 'upperLimit': '24'}, {'value': '24', 'groupId': 'OG002', 'lowerLimit': '24', 'upperLimit': '72'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '24', 'groupId': 'OG004', 'lowerLimit': '24', 'upperLimit': '48'}, {'value': '24', 'groupId': 'OG005', 'lowerLimit': '24', 'upperLimit': '24'}]}]}, {'title': '5th percentile', 'categories': [{'measurements': [{'value': '24', 'groupId': 'OG000', 'lowerLimit': '24', 'upperLimit': '24'}, {'value': '48', 'comment': 'Not estimable as the upper limit for survival function at all weeks is above 95%', 'groupId': 'OG001', 'lowerLimit': '24', 'upperLimit': 'NA'}, {'value': '72', 'comment': 'Not estimable as the upper limit for survival function at all weeks is above 95%', 'groupId': 'OG002', 'lowerLimit': '24', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '48', 'comment': 'Not estimable as the upper limit for survival function at all weeks is above 95%', 'groupId': 'OG004', 'lowerLimit': '24', 'upperLimit': 'NA'}, {'value': '24', 'groupId': 'OG005', 'lowerLimit': '24', 'upperLimit': '48'}]}]}, {'title': '10th percentile', 'categories': [{'measurements': [{'value': '24', 'groupId': 'OG000', 'lowerLimit': '24', 'upperLimit': '24'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for survival function at all weeks is above 90%', 'groupId': 'OG001', 'lowerLimit': '24', 'upperLimit': 'NA'}, {'value': '144', 'comment': 'Not estimable as the upper limit for survival function at all weeks is above 90%', 'groupId': 'OG002', 'lowerLimit': '48', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '120', 'comment': 'Not estimable as the upper limit for survival function at all weeks is above 90%', 'groupId': 'OG004', 'lowerLimit': '24', 'upperLimit': 'NA'}, {'value': '24', 'comment': 'Not estimable as the upper limit for survival function at all weeks is above 90%', 'groupId': 'OG005', 'lowerLimit': '24', 'upperLimit': 'NA'}]}]}, {'title': '25th percentile', 'categories': [{'measurements': [{'value': '24', 'groupId': 'OG000', 'lowerLimit': '24', 'upperLimit': '24'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for survival function at all weeks is above 75%', 'groupId': 'OG002', 'lowerLimit': '144', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for survival function at all weeks is above 75%', 'groupId': 'OG004', 'lowerLimit': '120', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for survival function at all weeks is above 75%', 'groupId': 'OG005', 'lowerLimit': '24', 'upperLimit': 'NA'}]}]}, {'title': '50th percentile', 'categories': [{'measurements': [{'value': '60', 'groupId': 'OG000', 'lowerLimit': '48', 'upperLimit': '96'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 50%', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 50%', 'groupId': 'OG002', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 50%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for survival function at all weeks is above 50%', 'groupId': 'OG004', 'lowerLimit': '120', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 50%', 'groupId': 'OG005', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From week 24 through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure \\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry (to allow for 14 day window for scheduling the visit). HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement, allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure. Event times were the scheduled week of the initial failing measurement (RNA scheduled at week 0, 12, 24, 48 and every 24 weeks after). Censoring times were the scheduled week of the last RNA result. Length of follow-up varied by Cohort.', 'unitOfMeasure': 'weeks', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All enrolled participants'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'categories': [{'measurements': [{'value': '145', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From week 24 through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure \\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry (to allow for 14 day window for scheduling the visit). HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement, allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure. Length of follow-up varied by Cohort.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'All enrolled participants'}, {'type': 'SECONDARY', 'title': 'Percent of Participants With Confirmed Virologic Failure by Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'categories': [{'measurements': [{'value': '48.9', 'groupId': 'OG000', 'lowerLimit': '42.8', 'upperLimit': '54.7'}, {'value': '8.2', 'groupId': 'OG001', 'lowerLimit': '3.3', 'upperLimit': '16.0'}, {'value': '2.9', 'groupId': 'OG002', 'lowerLimit': '0.1', 'upperLimit': '9.0'}, {'value': '0', 'comment': 'Not estimated due to lack of events in group by week 48', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '5.8', 'groupId': 'OG004', 'lowerLimit': '1.9', 'upperLimit': '13.1'}, {'value': '18.6', 'groupId': 'OG005', 'lowerLimit': '7.4', 'upperLimit': '33.8'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From week 24 to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure \\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry(to allow for 14 day window for scheduling the visit). HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement,allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure. Event times were the scheduled week of the initial failing measurement (RNA scheduled at week 0, 12, 24, 48 and every 24 weeks after). Censoring times were the scheduled week of the last RNA result. Length of follow-up varied by Cohort.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All enrolled participants'}, {'type': 'SECONDARY', 'title': 'Time to Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'title': '1st percentile', 'categories': [{'measurements': [{'value': '24', 'groupId': 'OG000', 'lowerLimit': '24', 'upperLimit': '24'}, {'value': '24', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG001', 'lowerLimit': '24', 'upperLimit': 'NA'}, {'value': '24', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG002', 'lowerLimit': '24', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '48', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG004', 'lowerLimit': '48', 'upperLimit': 'NA'}, {'value': '24', 'groupId': 'OG005', 'lowerLimit': '24', 'upperLimit': '24'}]}]}, {'title': '5th percentile', 'categories': [{'measurements': [{'value': '24', 'groupId': 'OG000', 'lowerLimit': '24', 'upperLimit': '24'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for survival function at all weeks is above 95%', 'groupId': 'OG001', 'lowerLimit': '24', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for survival function at all weeks is above 95%', 'groupId': 'OG002', 'lowerLimit': '24', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for survival function at all weeks is above 95%', 'groupId': 'OG004', 'lowerLimit': '48', 'upperLimit': 'NA'}, {'value': '24', 'groupId': 'OG005', 'lowerLimit': '24', 'upperLimit': '48'}]}]}, {'title': '10th percentile', 'categories': [{'measurements': [{'value': '24', 'groupId': 'OG000', 'lowerLimit': '24', 'upperLimit': '48'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for survival function at all weeks is above 90%', 'groupId': 'OG002', 'lowerLimit': '72', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for survival function at all weeks is above 90%', 'groupId': 'OG004', 'lowerLimit': '48', 'upperLimit': 'NA'}, {'value': '24', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG005', 'lowerLimit': '24', 'upperLimit': 'NA'}]}]}, {'title': '25th percentile', 'categories': [{'measurements': [{'value': '144', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG000', 'lowerLimit': '72', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG002', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG004', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG005', 'lowerLimit': '24', 'upperLimit': 'NA'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From week 24 through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure \\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry (to allow for 14 day window for scheduling the visit). HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement, allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure. Event times were the scheduled week of the initial failing measurement (RNA scheduled at week 0, 12, 24, 48 and every 24 weeks after). Censoring times were the scheduled week of the last RNA result. Length of follow-up varied by Cohort. A new resistance-associated mutation is defined as one not present in the genotype prior to entry.', 'unitOfMeasure': 'weeks', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All enrolled participants'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'categories': [{'measurements': [{'value': '48', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From week 24 through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure\\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry (to allow for 14 day window for scheduling the visit).HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement, allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure. Length of follow-up varied by Cohort. A new resistance-associated mutation is defined as one not present in the genotype prior to entry.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'All enrolled participants'}, {'type': 'SECONDARY', 'title': 'Percent of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing, by Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'categories': [{'measurements': [{'value': '16.6', 'groupId': 'OG000', 'lowerLimit': '12.3', 'upperLimit': '21.5'}, {'value': '1.4', 'groupId': 'OG001', 'lowerLimit': '0.1', 'upperLimit': '6.6'}, {'value': '1.4', 'groupId': 'OG002', 'lowerLimit': '0.1', 'upperLimit': '6.7'}, {'value': '0', 'comment': 'Not estimated due to lack of events in group by week 48', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '1.5', 'groupId': 'OG004', 'lowerLimit': '0.1', 'upperLimit': '7.1'}, {'value': '15.4', 'groupId': 'OG005', 'lowerLimit': '5.5', 'upperLimit': '29.9'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From week 24 to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure\\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry(to allow for 14 day window for scheduling the visit).HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement,allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure.Event times were the scheduled week of the initial failing measurement(RNA scheduled at week 0, 12, 24, 48 and every 24 weeks after).Censoring times were the scheduled week of the last RNA result.Length of follow-up varied by Cohort.A new resistance-associated mutation is defined as one not present in the genotype prior to entry.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All enrolled participants'}, {'type': 'SECONDARY', 'title': 'Time From Study Entry/Randomization to Death', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'title': '1st percentile', 'categories': [{'measurements': [{'value': '11.3', 'groupId': 'OG000', 'lowerLimit': '4.0', 'upperLimit': '17.7'}, {'value': '3.1', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG001', 'lowerLimit': '3.1', 'upperLimit': 'NA'}, {'value': '44.6', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG002', 'lowerLimit': '44.6', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '77.9', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG004', 'lowerLimit': '77.9', 'upperLimit': 'NA'}, {'value': '2.4', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG005', 'lowerLimit': '2.4', 'upperLimit': 'NA'}]}]}, {'title': '5th percentile', 'categories': [{'measurements': [{'value': '62.4', 'groupId': 'OG000', 'lowerLimit': '17.7', 'upperLimit': '110.1'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG001', 'lowerLimit': '3.1', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG002', 'lowerLimit': '44.6', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG004', 'lowerLimit': '77.9', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG005', 'lowerLimit': '2.4', 'upperLimit': 'NA'}]}]}, {'title': '10th percentile', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG000', 'lowerLimit': '82.1', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG002', 'lowerLimit': '51.4', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG004', 'lowerLimit': '77.9', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG005', 'lowerLimit': '2.4', 'upperLimit': 'NA'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Event time was the exact week of death. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit. Length of follow-up varied by Cohort.', 'unitOfMeasure': 'weeks', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'all enrolled participants'}, {'type': 'SECONDARY', 'title': 'Percent of Participants Experiencing Death by Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'categories': [{'measurements': [{'value': '3.9', 'groupId': 'OG000', 'lowerLimit': '2.0', 'upperLimit': '6.6'}, {'value': '1.4', 'groupId': 'OG001', 'lowerLimit': '0.1', 'upperLimit': '6.5'}, {'value': '1.4', 'groupId': 'OG002', 'lowerLimit': '0.1', 'upperLimit': '6.7'}, {'value': '0', 'comment': 'Not estimated due to lack of events in group by week 48', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '0', 'comment': 'Not estimated due to lack of events in group by week 48', 'groupId': 'OG004', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '2.9', 'groupId': 'OG005', 'lowerLimit': '0.2', 'upperLimit': '13.2'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Event time was the exact week of death. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'all enrolled participants'}, {'type': 'SECONDARY', 'title': 'Time From Study Entry/Randomization to the First of Death, an AIDS-defining Event or a Non-AIDS-defining Event', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'title': '1st percentile', 'categories': [{'measurements': [{'value': '4.0', 'groupId': 'OG000', 'lowerLimit': '4.0', 'upperLimit': '11.3'}, {'value': '3.1', 'groupId': 'OG001', 'lowerLimit': '3.1', 'upperLimit': '34.0'}, {'value': '16.3', 'groupId': 'OG002', 'lowerLimit': '16.3', 'upperLimit': '44.6'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '3.3', 'groupId': 'OG004', 'lowerLimit': '3.3', 'upperLimit': '26.6'}, {'value': '2.4', 'groupId': 'OG005', 'lowerLimit': '2.4', 'upperLimit': '24.0'}]}]}, {'title': '5th percentile', 'categories': [{'measurements': [{'value': '27.6', 'groupId': 'OG000', 'lowerLimit': '11.3', 'upperLimit': '42.9'}, {'value': '36.0', 'groupId': 'OG001', 'lowerLimit': '3.1', 'upperLimit': '84.0'}, {'value': '50.3', 'groupId': 'OG002', 'lowerLimit': '16.3', 'upperLimit': '120.0'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '36.0', 'groupId': 'OG004', 'lowerLimit': '3.3', 'upperLimit': '119.1'}, {'value': '24.0', 'groupId': 'OG005', 'lowerLimit': '2.4', 'upperLimit': '72.0'}]}]}, {'title': '10th percentile', 'categories': [{'measurements': [{'value': '57.9', 'groupId': 'OG000', 'lowerLimit': '37.3', 'upperLimit': '79.7'}, {'value': '84.0', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG001', 'lowerLimit': '4.6', 'upperLimit': 'NA'}, {'value': '120.0', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG002', 'lowerLimit': '36.0', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '77.9', 'groupId': 'OG004', 'lowerLimit': '3.6', 'upperLimit': '142.4'}, {'value': '48.4', 'groupId': 'OG005', 'lowerLimit': '2.4', 'upperLimit': '84.0'}]}]}, {'title': '25th percentile', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG000', 'lowerLimit': '118.6', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG001', 'lowerLimit': '88.7', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG002', 'lowerLimit': '120.0', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '142.4', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG004', 'lowerLimit': '119.1', 'upperLimit': 'NA'}, {'value': '96.3', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG005', 'lowerLimit': '48.4', 'upperLimit': 'NA'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Event time was the exact week of death, AIDS-defining event or non-AIDS defining event. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit. Only new events were considered, an event that was also reported at or prior to study entry was not included. If a participant experienced multiple events, then the time of the first event was used in the analysis. AIDS defining events included parasitic, fungal, bacterial, and viral infections as well as neoplastic diseases, and neurological disorders. Non-AIDS defining events included malignancies, diabetes, neuropathies, cardiac and renal events. Length of follow-up varied by Cohort.', 'unitOfMeasure': 'weeks', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'all enrolled participants'}, {'type': 'SECONDARY', 'title': 'Percent of Participants Experiencing Death, AIDS-defining Event or a Non-AIDS-defining Event by Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'categories': [{'measurements': [{'value': '8.8', 'groupId': 'OG000', 'lowerLimit': '5.9', 'upperLimit': '12.4'}, {'value': '5.4', 'groupId': 'OG001', 'lowerLimit': '1.7', 'upperLimit': '12.2'}, {'value': '4.2', 'groupId': 'OG002', 'lowerLimit': '1.1', 'upperLimit': '10.7'}, {'value': '0', 'comment': 'Not estimated due to lack of events in group by week 48', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '5.8', 'groupId': 'OG004', 'lowerLimit': '1.8', 'upperLimit': '13.0'}, {'value': '5.9', 'groupId': 'OG005', 'lowerLimit': '1.0', 'upperLimit': '17.4'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Event time was the exact week of death, AIDS-defining event or non-AIDS defining event. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit. Only new events were considered, an event that was also reported at or prior to study entry was not included. If a participant experienced multiple events, then the time of the first event was used in the analysis. AIDS defining events included parasitic, fungal, bacterial, and viral infections as well as neoplastic diseases, and neurological disorders. Non-AIDS defining events included malignancies, diabetes, neuropathies, cardiac and renal events.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'all enrolled participants'}, {'type': 'SECONDARY', 'title': 'Time From Study Entry/Randomization to the First of Death or Hospitalization.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'title': '1st percentile', 'categories': [{'measurements': [{'value': '2.4', 'groupId': 'OG000', 'lowerLimit': '1.0', 'upperLimit': '5.9'}, {'value': '2.3', 'groupId': 'OG001', 'lowerLimit': '2.3', 'upperLimit': '10.9'}, {'value': '3.0', 'groupId': 'OG002', 'lowerLimit': '3.0', 'upperLimit': '25.6'}, {'value': '16.4', 'groupId': 'OG003', 'lowerLimit': '16.4', 'upperLimit': '16.4'}, {'value': '2.0', 'groupId': 'OG004', 'lowerLimit': '2.0', 'upperLimit': '3.3'}, {'value': '2.3', 'groupId': 'OG005', 'lowerLimit': '2.3', 'upperLimit': '5.6'}]}]}, {'title': '5th percentile', 'categories': [{'measurements': [{'value': '13.4', 'groupId': 'OG000', 'lowerLimit': '5.9', 'upperLimit': '25.1'}, {'value': '20.3', 'groupId': 'OG001', 'lowerLimit': '2.3', 'upperLimit': '100.1'}, {'value': '28.0', 'groupId': 'OG002', 'lowerLimit': '3.0', 'upperLimit': '49.7'}, {'value': '16.4', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG003', 'lowerLimit': '16.4', 'upperLimit': 'NA'}, {'value': '7.7', 'groupId': 'OG004', 'lowerLimit': '2.0', 'upperLimit': '84.9'}, {'value': '5.6', 'groupId': 'OG005', 'lowerLimit': '2.3', 'upperLimit': '96.1'}]}]}, {'title': '10th percentile', 'categories': [{'measurements': [{'value': '32.6', 'groupId': 'OG000', 'lowerLimit': '22.9', 'upperLimit': '61.1'}, {'value': '80.7', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG001', 'lowerLimit': '9.1', 'upperLimit': 'NA'}, {'value': '49.7', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG002', 'lowerLimit': '6.1', 'upperLimit': 'NA'}, {'value': '16.4', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG003', 'lowerLimit': '16.4', 'upperLimit': 'NA'}, {'value': '77.9', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG004', 'lowerLimit': '2.0', 'upperLimit': 'NA'}, {'value': '96.1', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG005', 'lowerLimit': '2.3', 'upperLimit': 'NA'}]}]}, {'title': '25th percentile', 'categories': [{'measurements': [{'value': '120.1', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG000', 'lowerLimit': '97.3', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG001', 'lowerLimit': '100.1', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG002', 'lowerLimit': '90.7', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG003', 'lowerLimit': '16.4', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG004', 'lowerLimit': '84.9', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG005', 'lowerLimit': '96.1', 'upperLimit': 'NA'}]}]}, {'title': '50th percentile', 'categories': [{'measurements': [{'value': '168.9', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 50%', 'groupId': 'OG000', 'lowerLimit': '168.9', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 50%', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 50%', 'groupId': 'OG002', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 50%', 'groupId': 'OG003', 'lowerLimit': '16.4', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 50%', 'groupId': 'OG004', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 50%', 'groupId': 'OG005', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Event time was the exact week of death or hospitalization. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit. If a participant experienced multiple events, then the time of the first event was used in the analysis. Length of follow-up varied by Cohort.', 'unitOfMeasure': 'weeks', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'all enrolled participants'}, {'type': 'SECONDARY', 'title': 'Percent of Participants With Death or Hospitalization by Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'categories': [{'measurements': [{'value': '12.3', 'groupId': 'OG000', 'lowerLimit': '8.8', 'upperLimit': '16.4'}, {'value': '8.1', 'groupId': 'OG001', 'lowerLimit': '3.3', 'upperLimit': '15.8'}, {'value': '9.7', 'groupId': 'OG002', 'lowerLimit': '4.2', 'upperLimit': '17.9'}, {'value': '12.5', 'groupId': 'OG003', 'lowerLimit': '0.5', 'upperLimit': '44.5'}, {'value': '5.7', 'groupId': 'OG004', 'lowerLimit': '1.8', 'upperLimit': '12.9'}, {'value': '5.9', 'groupId': 'OG005', 'lowerLimit': '1.0', 'upperLimit': '17.4'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Event time was the exact week of death or hospitalization. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit. If a participant experienced multiple events, then the time of the first event was used in the analysis.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'all enrolled participants'}, {'type': 'SECONDARY', 'title': 'Time From Study Entry/Randomization to Treatment Modification or Discontinuation.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'title': '1st percentile', 'categories': [{'measurements': [{'value': '1.0', 'groupId': 'OG000', 'lowerLimit': '0.0', 'upperLimit': '4.1'}, {'value': '3.1', 'groupId': 'OG001', 'lowerLimit': '3.1', 'upperLimit': '28.9'}, {'value': '4.4', 'groupId': 'OG002', 'lowerLimit': '4.4', 'upperLimit': '9.4'}, {'value': '4.4', 'groupId': 'OG003', 'lowerLimit': '4.4', 'upperLimit': '4.4'}, {'value': '0.1', 'groupId': 'OG004', 'lowerLimit': '0.1', 'upperLimit': '3.7'}, {'value': '2.4', 'groupId': 'OG005', 'lowerLimit': '2.4', 'upperLimit': '5.1'}]}]}, {'title': '5th percentile', 'categories': [{'measurements': [{'value': '8.4', 'groupId': 'OG000', 'lowerLimit': '4.1', 'upperLimit': '18.9'}, {'value': '33.4', 'groupId': 'OG001', 'lowerLimit': '3.1', 'upperLimit': '59.0'}, {'value': '36.0', 'groupId': 'OG002', 'lowerLimit': '4.4', 'upperLimit': '38.6'}, {'value': '4.4', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG003', 'lowerLimit': '4.4', 'upperLimit': 'NA'}, {'value': '4.1', 'groupId': 'OG004', 'lowerLimit': '0.1', 'upperLimit': '29.7'}, {'value': '5.1', 'groupId': 'OG005', 'lowerLimit': '2.4', 'upperLimit': '48.6'}]}]}, {'title': '10th percentile', 'categories': [{'measurements': [{'value': '25.3', 'groupId': 'OG000', 'lowerLimit': '10.6', 'upperLimit': '34.3'}, {'value': '59.0', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG001', 'lowerLimit': '15.0', 'upperLimit': 'NA'}, {'value': '38.6', 'groupId': 'OG002', 'lowerLimit': '6.4', 'upperLimit': '44.6'}, {'value': '4.4', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG003', 'lowerLimit': '4.4', 'upperLimit': 'NA'}, {'value': '29.7', 'groupId': 'OG004', 'lowerLimit': '3.1', 'upperLimit': '61.4'}, {'value': '47.6', 'groupId': 'OG005', 'lowerLimit': '2.4', 'upperLimit': '55.0'}]}]}, {'title': '25th percentile', 'categories': [{'measurements': [{'value': '58.6', 'groupId': 'OG000', 'lowerLimit': '48.1', 'upperLimit': '84.0'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG001', 'lowerLimit': '117.6', 'upperLimit': 'NA'}, {'value': '165.6', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG002', 'lowerLimit': '43.0', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG003', 'lowerLimit': '4.4', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG004', 'lowerLimit': '58.6', 'upperLimit': 'NA'}, {'value': '98.9', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG005', 'lowerLimit': '47.6', 'upperLimit': 'NA'}]}]}, {'title': '50th percentile', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 50%', 'groupId': 'OG000', 'lowerLimit': '120.7', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 50%', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 50%', 'groupId': 'OG002', 'lowerLimit': '165.6', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 50%', 'groupId': 'OG003', 'lowerLimit': '4.4', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 50%', 'groupId': 'OG004', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 50%', 'groupId': 'OG005', 'lowerLimit': '98.9', 'upperLimit': 'NA'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Treatment modification is defined as the first occurrence of a substitution or subtraction of one or more drugs in the study regimen, a temporary hold lasting 7 days or longer, or the addition of a new drug to the regimen. This would not include splitting any fixed dose combination medications if the participant continues on the active drugs of the combination. Event time was the exact week of the modification or discontinuation. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit. Length of follow-up varied by Cohort.', 'unitOfMeasure': 'weeks', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'all enrolled participants'}, {'type': 'SECONDARY', 'title': 'Percent of Participants With Treatment Modification or Discontinuation by Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'categories': [{'measurements': [{'value': '19.9', 'groupId': 'OG000', 'lowerLimit': '15.5', 'upperLimit': '24.7'}, {'value': '6.8', 'groupId': 'OG001', 'lowerLimit': '2.5', 'upperLimit': '14.0'}, {'value': '19.4', 'groupId': 'OG002', 'lowerLimit': '11.2', 'upperLimit': '29.3'}, {'value': '12.5', 'groupId': 'OG003', 'lowerLimit': '0.5', 'upperLimit': '44.5'}, {'value': '14.3', 'groupId': 'OG004', 'lowerLimit': '7.3', 'upperLimit': '23.6'}, {'value': '11.8', 'groupId': 'OG005', 'lowerLimit': '3.6', 'upperLimit': '25.1'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Treatment modification is defined as the first occurrence of a substitution or subtraction of one or more drugs in the study regimen, a temporary hold lasting 7 days or longer, or the addition of a new drug to the regimen. This would not include splitting any fixed dose combination medications if the participant continues on the active drugs of the combination. Event time was the exact week of the modification or discontinuation. Censoring time was the earliest time point between last dose week and the week of the last step 1/2 visit.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'all enrolled participants'}, {'type': 'SECONDARY', 'title': 'Time From Study Entry/Randomization to Treatment Modification or Discontinuation Due to Toxicity', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'title': '1st percentile', 'categories': [{'measurements': [{'value': '2.1', 'groupId': 'OG000', 'lowerLimit': '0.4', 'upperLimit': '32.3'}, {'value': '15.0', 'groupId': 'OG001', 'lowerLimit': '15.0', 'upperLimit': '49.1'}, {'value': '6.4', 'groupId': 'OG002', 'lowerLimit': '6.4', 'upperLimit': '134.0'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '0.1', 'groupId': 'OG004', 'lowerLimit': '0.1', 'upperLimit': '3.7'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG005', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': '5th percentile', 'categories': [{'measurements': [{'value': '106.1', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG000', 'lowerLimit': '32.3', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG001', 'lowerLimit': '15.0', 'upperLimit': 'NA'}, {'value': '134.0', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG002', 'lowerLimit': '6.4', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG004', 'lowerLimit': '0.1', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG005', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': '10th percentile', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG000', 'lowerLimit': '106.1', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG001', 'lowerLimit': '41', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG002', 'lowerLimit': '134.0', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG004', 'lowerLimit': '3.1', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG005', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Treatment modification is defined as the first occurrence of a substitution or subtraction of one or more drugs in the study regimen, a temporary hold lasting 7 days or longer, or the addition of a new drug to the regimen, due to an adverse event. This would not include splitting any fixed dose combination medications if the participant continues on the active drugs of the combination. Event time was the exact week of the modification or discontinuation. Censoring time was the earliest time point between last dose week and the week of the last step 1/2 visit. Length of follow-up varied by Cohort. DAIDS AE Grading Table, Version 1.0 was used.', 'unitOfMeasure': 'weeks', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'all enrolled participants'}, {'type': 'SECONDARY', 'title': 'Percent of Participants With Treatment Modification or Discontinuation Due to Toxicity by Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'categories': [{'measurements': [{'value': '3.2', 'groupId': 'OG000', 'lowerLimit': '1.6', 'upperLimit': '5.8'}, {'value': '2.7', 'groupId': 'OG001', 'lowerLimit': '0.5', 'upperLimit': '8.6'}, {'value': '1.4', 'groupId': 'OG002', 'lowerLimit': '0.1', 'upperLimit': '6.7'}, {'value': '0', 'comment': 'Not estimated due to lack of events in group by week 48', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '4.3', 'groupId': 'OG004', 'lowerLimit': '1.1', 'upperLimit': '11.0'}, {'value': '0', 'comment': 'Not estimated due to lack of events in group by week 48', 'groupId': 'OG005', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Treatment modification is defined as the first occurrence of a substitution or subtraction of one or more drugs in the study regimen, a temporary hold lasting 7 days or longer, or the addition of a new drug to the regimen, due to an adverse event. This would not include splitting any fixed dose combination medications if the participant continues on the active drugs of the combination. Event time was the exact week of the modification or discontinuation. Censoring time was the earliest time point between last dose week and the week of the last step 1/2 visit. DAIDS AE Grading Table, Version 1.0 was used.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'all enrolled participants'}, {'type': 'SECONDARY', 'title': 'Time From Study Entry/Randomization to the Development of Immune Reconstitution Inflammatory Syndrome (IRIS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'title': '1st percentile', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG000', 'lowerLimit': '9.0', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '25.0', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG002', 'lowerLimit': '25.0', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG004', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '13.0', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG005', 'lowerLimit': '13.0', 'upperLimit': 'NA'}]}]}, {'title': '5th percentile', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG002', 'lowerLimit': '25.0', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG004', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG005', 'lowerLimit': '13.0', 'upperLimit': 'NA'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Event time was the exact week of the diagnosis. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit. Length of follow-up varied by Cohort.', 'unitOfMeasure': 'weeks', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'all enrolled participants'}, {'type': 'SECONDARY', 'title': 'Percent of Participants That Developed Immune Reconstitution Inflammatory Syndrome (IRIS) by Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'categories': [{'measurements': [{'value': '0.7', 'groupId': 'OG000', 'lowerLimit': '0.1', 'upperLimit': '2.4'}, {'value': '0', 'comment': 'Not estimated due to lack of events in group by week 48', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '1.4', 'groupId': 'OG002', 'lowerLimit': '0.1', 'upperLimit': '6.7'}, {'value': '0', 'comment': 'Not estimated due to lack of events in group by week 48', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '0', 'comment': 'Not estimated due to lack of events in group by week 48', 'groupId': 'OG004', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '3.0', 'groupId': 'OG005', 'lowerLimit': '0.2', 'upperLimit': '13.6'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry to week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Event time was the exact week of the diagnosis. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'all enrolled participants'}, {'type': 'SECONDARY', 'title': 'Time to First Dose Modification Due to Grade 3 or 4 Toxicity', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'title': '1st percentile', 'categories': [{'measurements': [{'value': '45.7', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG000', 'lowerLimit': '5.9', 'upperLimit': 'NA'}, {'value': '63.3', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG001', 'lowerLimit': '63.3', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG002', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG004', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG005', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': '5th percentile', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG001', 'lowerLimit': '63.3', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG002', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG004', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG005', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Event time was the exact week of the modification. Censoring time was the earliest time point between last dose week and the week of the last step 1/2 visit. Length of follow-up varied by Cohort. DAIDS AE Grading Table, Version 1.0 was used.', 'unitOfMeasure': 'weeks', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'all enrolled participants'}, {'type': 'SECONDARY', 'title': 'Percent of Participants With a Dose Modification Due to Grade 3 or 4 Toxicity by Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'categories': [{'measurements': [{'value': '1.0', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '2.8'}, {'value': '0', 'comment': 'Not estimated due to lack of events in group by week 48', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '0', 'comment': 'Not estimated due to lack of events in group by week 48', 'groupId': 'OG002', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '0', 'comment': 'Not estimated due to lack of events in group by week 48', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '0', 'comment': 'Not estimated due to lack of events in group by week 48', 'groupId': 'OG004', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '0', 'comment': 'Not estimated due to lack of events in group by week 48', 'groupId': 'OG005', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry to week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Event time was the exact week of the modification. Censoring time was the earliest time point between last dose week and the week of the last step 1/2 visit. DAIDS AE Grading Table, Version 1.0 was used.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'all enrolled participants'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in CD4+ T-cell Count', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'title': 'Change from baseline at week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '267', 'groupId': 'OG000'}, {'value': '70', 'groupId': 'OG001'}, {'value': '71', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '69', 'groupId': 'OG004'}, {'value': '33', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '39', 'spread': '105', 'groupId': 'OG000'}, {'value': '109', 'spread': '133', 'groupId': 'OG001'}, {'value': '116', 'spread': '130', 'groupId': 'OG002'}, {'value': '142', 'spread': '99', 'groupId': 'OG003'}, {'value': '100', 'spread': '121', 'groupId': 'OG004'}, {'value': '90', 'spread': '131', 'groupId': 'OG005'}]}]}, {'title': 'Change from baseline at week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '258', 'groupId': 'OG000'}, {'value': '71', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '69', 'groupId': 'OG004'}, {'value': '31', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '65', 'spread': '138', 'groupId': 'OG000'}, {'value': '157', 'spread': '162', 'groupId': 'OG001'}, {'value': '158', 'spread': '172', 'groupId': 'OG002'}, {'value': '86', 'spread': '166', 'groupId': 'OG003'}, {'value': '160', 'spread': '140', 'groupId': 'OG004'}, {'value': '135', 'spread': '214', 'groupId': 'OG005'}]}]}, {'title': 'Change from baseline at week 72', 'denoms': [{'units': 'Participants', 'counts': [{'value': '207', 'groupId': 'OG000'}, {'value': '59', 'groupId': 'OG001'}, {'value': '58', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '52', 'groupId': 'OG004'}, {'value': '30', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '87', 'spread': '165', 'groupId': 'OG000'}, {'value': '182', 'spread': '153', 'groupId': 'OG001'}, {'value': '197', 'spread': '199', 'groupId': 'OG002'}, {'value': '238', 'spread': '86', 'groupId': 'OG003'}, {'value': '185', 'spread': '151', 'groupId': 'OG004'}, {'value': '165', 'spread': '270', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, week 24, 48, and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen (this second date applies only to Cohorts B, C and D as there is no change of regimen for patients in Cohort A)', 'unitOfMeasure': 'cells/mm^3', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'all enrolled participants with results available at baseline and at the given follow-up time point'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Fasting Values of Total Cholesterol', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'title': 'Change from baseline at week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '195', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}, {'value': '51', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '54', 'groupId': 'OG004'}, {'value': '25', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '5.7', 'spread': '33.0', 'groupId': 'OG000'}, {'value': '16.7', 'spread': '41.8', 'groupId': 'OG001'}, {'value': '32.5', 'spread': '43.3', 'groupId': 'OG002'}, {'value': '12.4', 'spread': '27.5', 'groupId': 'OG003'}, {'value': '16.5', 'spread': '36.5', 'groupId': 'OG004'}, {'value': '7.9', 'spread': '43.5', 'groupId': 'OG005'}]}]}, {'title': 'Change from baseline at week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '189', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '48', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '57', 'groupId': 'OG004'}, {'value': '22', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '4.4', 'spread': '36.0', 'groupId': 'OG000'}, {'value': '19.7', 'spread': '41.1', 'groupId': 'OG001'}, {'value': '40.4', 'spread': '46.9', 'groupId': 'OG002'}, {'value': '9.9', 'spread': '21.6', 'groupId': 'OG003'}, {'value': '20.0', 'spread': '34.6', 'groupId': 'OG004'}, {'value': '19.1', 'spread': '32.0', 'groupId': 'OG005'}]}]}, {'title': 'Change from baseline at week 72', 'denoms': [{'units': 'Participants', 'counts': [{'value': '149', 'groupId': 'OG000'}, {'value': '41', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '20', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '7.6', 'spread': '33.4', 'groupId': 'OG000'}, {'value': '22.6', 'spread': '47.8', 'groupId': 'OG001'}, {'value': '40.4', 'spread': '51.0', 'groupId': 'OG002'}, {'value': '28.2', 'spread': '42.9', 'groupId': 'OG003'}, {'value': '22.1', 'spread': '35.5', 'groupId': 'OG004'}, {'value': '24.5', 'spread': '33.9', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, week 24, 48 and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen (this second date applies only to Cohorts B, C and D as there is no change of regimen for patients in Cohort A)', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'all enrolled participants with results available at baseline and at the given follow-up time point'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Fasting Values of High-density Lipoprotein Cholesterol', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'title': 'Change from baseline at week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '181', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}, {'value': '49', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '54', 'groupId': 'OG004'}, {'value': '24', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '2.8', 'spread': '14.7', 'groupId': 'OG000'}, {'value': '3.2', 'spread': '11.7', 'groupId': 'OG001'}, {'value': '11.4', 'spread': '16.8', 'groupId': 'OG002'}, {'value': '2.1', 'spread': '4.3', 'groupId': 'OG003'}, {'value': '1.0', 'spread': '13.2', 'groupId': 'OG004'}, {'value': '-2.2', 'spread': '11.3', 'groupId': 'OG005'}]}]}, {'title': 'Change from baseline at week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '183', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '47', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '58', 'groupId': 'OG004'}, {'value': '23', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '3.5', 'spread': '13.9', 'groupId': 'OG000'}, {'value': '5.3', 'spread': '10.3', 'groupId': 'OG001'}, {'value': '13.4', 'spread': '13.8', 'groupId': 'OG002'}, {'value': '3.8', 'spread': '2.9', 'groupId': 'OG003'}, {'value': '2.3', 'spread': '12.2', 'groupId': 'OG004'}, {'value': '1.8', 'spread': '12.2', 'groupId': 'OG005'}]}]}, {'title': 'Change from baseline at week 72', 'denoms': [{'units': 'Participants', 'counts': [{'value': '143', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '19', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '4.7', 'spread': '14.1', 'groupId': 'OG000'}, {'value': '4.4', 'spread': '11.4', 'groupId': 'OG001'}, {'value': '15.7', 'spread': '15.1', 'groupId': 'OG002'}, {'value': '4.6', 'spread': '3.6', 'groupId': 'OG003'}, {'value': '5.8', 'spread': '13.2', 'groupId': 'OG004'}, {'value': '3.4', 'spread': '12.8', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, week 24, 48 and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen (this second date applies only to Cohorts B, C and D as there is no change of regimen for patients in Cohort A)\\]', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'all enrolled participants with results available at baseline and at the given follow-up time point'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Fasting Values of Calculated Low-density Lipoprotein Cholesterol', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'title': 'Change from baseline at week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '193', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}, {'value': '51', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '52', 'groupId': 'OG004'}, {'value': '24', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '1.3', 'spread': '25.2', 'groupId': 'OG000'}, {'value': '13.3', 'spread': '34.4', 'groupId': 'OG001'}, {'value': '21.5', 'spread': '31.6', 'groupId': 'OG002'}, {'value': '-0.5', 'spread': '11.3', 'groupId': 'OG003'}, {'value': '12.2', 'spread': '25.4', 'groupId': 'OG004'}, {'value': '9.9', 'spread': '26.9', 'groupId': 'OG005'}]}]}, {'title': 'Change from baseline at week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '185', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '45', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}, {'value': '56', 'groupId': 'OG004'}, {'value': '22', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '3.4', 'spread': '28.5', 'groupId': 'OG000'}, {'value': '16.3', 'spread': '32.8', 'groupId': 'OG001'}, {'value': '28.2', 'spread': '38.1', 'groupId': 'OG002'}, {'value': '0.3', 'spread': '17.0', 'groupId': 'OG003'}, {'value': '15.3', 'spread': '25.7', 'groupId': 'OG004'}, {'value': '14.4', 'spread': '25.2', 'groupId': 'OG005'}]}]}, {'title': 'Change from baseline at week 72', 'denoms': [{'units': 'Participants', 'counts': [{'value': '148', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '39', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '18', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '3.9', 'spread': '26.6', 'groupId': 'OG000'}, {'value': '22.4', 'spread': '38.6', 'groupId': 'OG001'}, {'value': '27.8', 'spread': '40.1', 'groupId': 'OG002'}, {'value': '16.6', 'spread': '37.2', 'groupId': 'OG003'}, {'value': '13.6', 'spread': '25.8', 'groupId': 'OG004'}, {'value': '19.7', 'spread': '27.4', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, week 24, 48 and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen (this second date applies only to Cohorts B, C and D as there is no change of regimen for patients in Cohort A)', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'all enrolled participants with results available at baseline and at the given follow-up time point'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Fasting Values of Triglycerides', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'title': 'Change from baseline at week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '192', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '53', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '50', 'groupId': 'OG004'}, {'value': '24', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '15.4', 'spread': '75.7', 'groupId': 'OG000'}, {'value': '-3.6', 'spread': '84.9', 'groupId': 'OG001'}, {'value': '27.6', 'spread': '112.5', 'groupId': 'OG002'}, {'value': '36.0', 'spread': '48.1', 'groupId': 'OG003'}, {'value': '15.4', 'spread': '84.4', 'groupId': 'OG004'}, {'value': '28.9', 'spread': '65.5', 'groupId': 'OG005'}]}]}, {'title': 'Change from baseline at week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '184', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '49', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '53', 'groupId': 'OG004'}, {'value': '23', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '12.2', 'spread': '70.8', 'groupId': 'OG000'}, {'value': '-11.5', 'spread': '136.7', 'groupId': 'OG001'}, {'value': '19.9', 'spread': '84.1', 'groupId': 'OG002'}, {'value': '22.2', 'spread': '57.2', 'groupId': 'OG003'}, {'value': '9.9', 'spread': '65.9', 'groupId': 'OG004'}, {'value': '24.4', 'spread': '90.1', 'groupId': 'OG005'}]}]}, {'title': 'Change from baseline at week 72', 'denoms': [{'units': 'Participants', 'counts': [{'value': '144', 'groupId': 'OG000'}, {'value': '40', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '22', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '17.5', 'spread': '79.1', 'groupId': 'OG000'}, {'value': '-31.3', 'spread': '122.3', 'groupId': 'OG001'}, {'value': '18.9', 'spread': '99.4', 'groupId': 'OG002'}, {'value': '20.7', 'spread': '56.3', 'groupId': 'OG003'}, {'value': '11.8', 'spread': '83.9', 'groupId': 'OG004'}, {'value': '6.7', 'spread': '71.1', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, week 24, 48 and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen (this second date applies only to Cohorts B, C and D as there is no change of regimen for patients in Cohort A)', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'all enrolled participants with results available at baseline and at the given follow-up time point'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Fasting Values of Glucose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '72', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '70', 'groupId': 'OG004'}, {'value': '34', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'OG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'OG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'OG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'OG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'OG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}], 'classes': [{'title': 'Change from baseline at week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '195', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}, {'value': '51', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '52', 'groupId': 'OG004'}, {'value': '27', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '1.9', 'spread': '25.0', 'groupId': 'OG000'}, {'value': '8.8', 'spread': '18.9', 'groupId': 'OG001'}, {'value': '6.1', 'spread': '22.3', 'groupId': 'OG002'}, {'value': '6.6', 'spread': '8.3', 'groupId': 'OG003'}, {'value': '2.1', 'spread': '19.9', 'groupId': 'OG004'}, {'value': '3.2', 'spread': '19.1', 'groupId': 'OG005'}]}]}, {'title': 'Change from baseline at week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '183', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '49', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '55', 'groupId': 'OG004'}, {'value': '25', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '2.1', 'spread': '19.8', 'groupId': 'OG000'}, {'value': '9.3', 'spread': '28.5', 'groupId': 'OG001'}, {'value': '6.2', 'spread': '20.1', 'groupId': 'OG002'}, {'value': '1.7', 'spread': '6.9', 'groupId': 'OG003'}, {'value': '3.0', 'spread': '16.7', 'groupId': 'OG004'}, {'value': '4.2', 'spread': '13.7', 'groupId': 'OG005'}]}]}, {'title': 'Change from baseline at week 72', 'denoms': [{'units': 'Participants', 'counts': [{'value': '146', 'groupId': 'OG000'}, {'value': '42', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '23', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '3.0', 'spread': '29.7', 'groupId': 'OG000'}, {'value': '6.8', 'spread': '23.8', 'groupId': 'OG001'}, {'value': '-5.2', 'spread': '79.1', 'groupId': 'OG002'}, {'value': '4.3', 'spread': '7.6', 'groupId': 'OG003'}, {'value': '-0.9', 'spread': '17.9', 'groupId': 'OG004'}, {'value': '7.8', 'spread': '13.7', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, week 24, 48 and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen (this second date applies only to Cohorts B, C and D as there is no change of regimen for patients in Cohort A)', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'all enrolled participants with results available at baseline and at the given follow-up time point'}, {'type': 'SECONDARY', 'title': 'Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 48 Weeks [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.66', 'groupId': 'OG000', 'lowerLimit': '0.60', 'upperLimit': '0.72'}, {'value': '0.62', 'groupId': 'OG001', 'lowerLimit': '0.56', 'upperLimit': '0.68'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '48 weeks after the date of entry', 'description': 'The measurement closest to exactly 48 weeks (ie, 7x48=336 days) after the date of entry, within the window of 48 weeks ± 6 weeks (specifically 295 to 378 days after randomization, inclusive).\n\nThe analysis in the protocol and in the Stat. Analysis Plan involved estimating the proportion of participants in the overall study population with HIV-1 RNA ≤200 copies/mL at week 48 with a 95% confidence interval calculated via a Wald approach. Death or lost to follow-up before week 48 was considered as HIV-1 RNA\\>200 copies/mL at week 48. Missing results at week 48 were considered as HIV-1 RNA \\>200 copies/mL at week 48 unless the immediately preceding and succeeding HIV-1 RNA measurements were ≤200 copies/mL.', 'unitOfMeasure': 'proportion of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 24 Weeks [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.68', 'groupId': 'OG000', 'lowerLimit': '0.62', 'upperLimit': '0.73'}, {'value': '0.61', 'groupId': 'OG001', 'lowerLimit': '0.55', 'upperLimit': '0.67'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '24 weeks after the date of entry', 'description': 'The measurement closest to exactly 24 weeks (ie, 7x24=168 days) after the date of entry, within the window of 24 weeks ± 6 weeks (specifically 127 to 210 days after randomization, inclusive).\n\nThe analysis in the protocol and in the Stat. Analysis Plan involved estimating the proportion of participants in the overall study population with HIV-1 RNA ≤200 copies/mL at week 24 with a 95% confidence interval calculated via a Wald approach. Death or lost to follow-up before week 24 was considered as HIV-1 RNA\\>200 copies/mL at week 24. Missing results at week 24 were considered as HIV-1 RNA \\>200 copies/mL at week 24 unless the immediately preceding and succeeding HIV-1 RNA measurements were ≤200 copies/mL.', 'unitOfMeasure': 'proportion of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 72 Weeks [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '210', 'groupId': 'OG000'}, {'value': '217', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.69', 'groupId': 'OG000', 'lowerLimit': '0.62', 'upperLimit': '0.75'}, {'value': '0.62', 'groupId': 'OG001', 'lowerLimit': '0.55', 'upperLimit': '0.68'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '72 weeks after the date of entry', 'description': 'The measurement closest to exactly 72 weeks (ie, 7x72=504 days) after the date of entry, within the window of 72 weeks ± 6 weeks (specifically 463 to 546 days, inclusive).\n\nThe analysis in the protocol and in the Analysis Plan involved estimating the proportion of participants in the overall study population with HIV-1 RNA ≤200 copies/mL at week 72 with a 95% confidence interval calculated via a Wald approach. Death or lost to follow-up before week 72 was considered as HIV-1 RNA\\>200 copies/mL at week 72. If a result was expected, missing results at week 72 were considered as HIV-1 RNA \\>200 copies/mL at week 72 unless the immediately preceding and succeeding HIV-1 RNA measurements were ≤200 copies/mL.', 'unitOfMeasure': 'proportion of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC with results expected at week 72'}, {'type': 'SECONDARY', 'title': 'Number of Weeks of Follow-up [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'categories': [{'measurements': [{'value': '72', 'groupId': 'OG000', 'lowerLimit': '72', 'upperLimit': '108'}, {'value': '72', 'groupId': 'OG001', 'lowerLimit': '72', 'upperLimit': '108'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'From study entry through Step 1/2 follow-up', 'description': 'All participants were followed on step 1/2 until 48 weeks after the last participant was enrolled to step 1 regardless of virologic status or treatment switches.', 'unitOfMeasure': 'weeks', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Time to Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'title': '1st percentile', 'categories': [{'measurements': [{'value': '24', 'groupId': 'OG000', 'lowerLimit': '24', 'upperLimit': '24'}, {'value': '24', 'groupId': 'OG001', 'lowerLimit': '24', 'upperLimit': '24'}]}]}, {'title': '5th percentile', 'categories': [{'measurements': [{'value': '24', 'groupId': 'OG000', 'lowerLimit': '24', 'upperLimit': '24'}, {'value': '24', 'groupId': 'OG001', 'lowerLimit': '24', 'upperLimit': '24'}]}]}, {'title': '10th percentile', 'categories': [{'measurements': [{'value': '24', 'groupId': 'OG000', 'lowerLimit': '24', 'upperLimit': '24'}, {'value': '24', 'groupId': 'OG001', 'lowerLimit': '24', 'upperLimit': '24'}]}]}, {'title': '25th percentile', 'categories': [{'measurements': [{'value': '60', 'comment': 'Not estimable as the upper limit for survival function at all weeks is above 75%', 'groupId': 'OG000', 'lowerLimit': '48', 'upperLimit': 'NA'}, {'value': '24', 'groupId': 'OG001', 'lowerLimit': '24', 'upperLimit': '48'}]}]}, {'title': '50th percentile', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for survival function at all weeks is above 50%', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for survival function at all weeks is above 50%', 'groupId': 'OG001', 'lowerLimit': '144', 'upperLimit': 'NA'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From week 24 through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure \\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry (to allow for 14 day window for scheduling the visit). HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement, allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure. Event times were the scheduled week of the initial failing measurement (RNA scheduled at week 0, 12, 24, 48 and every 24 weeks after). Censoring times were the scheduled week of the last RNA result.', 'unitOfMeasure': 'weeks', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'categories': [{'measurements': [{'value': '66', 'groupId': 'OG000'}, {'value': '89', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From week 24 through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure \\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry (to allow for 14 day window for scheduling the visit). HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement, allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Percent of Participants With Confirmed Virologic Failure by Week 48 [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'categories': [{'measurements': [{'value': '24.9', 'groupId': 'OG000', 'lowerLimit': '19.6', 'upperLimit': '30.4'}, {'value': '32.2', 'groupId': 'OG001', 'lowerLimit': '26.6', 'upperLimit': '37.9'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From week 24 to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure \\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry(to allow for 14 day window for scheduling the visit). HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement,allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure. Event times were the scheduled week of the initial failing measurement (RNA scheduled at week 0, 12, 24, 48 and every 24 weeks after). Censoring times were the scheduled week of the last RNA result.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Time to Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'title': '1st percentile', 'categories': [{'measurements': [{'value': '24', 'groupId': 'OG000', 'lowerLimit': '24', 'upperLimit': '24'}, {'value': '24', 'groupId': 'OG001', 'lowerLimit': '24', 'upperLimit': '24'}]}]}, {'title': '5th percentile', 'categories': [{'measurements': [{'value': '24', 'groupId': 'OG000', 'lowerLimit': '24', 'upperLimit': '48'}, {'value': '24', 'groupId': 'OG001', 'lowerLimit': '24', 'upperLimit': '24'}]}]}, {'title': '10th percentile', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG000', 'lowerLimit': '24', 'upperLimit': 'NA'}, {'value': '48', 'groupId': 'OG001', 'lowerLimit': '24', 'upperLimit': '144'}]}]}, {'title': '25th percentile', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG001', 'lowerLimit': '144', 'upperLimit': 'NA'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From week 24 through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure \\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry (to allow for 14 day window for scheduling the visit). HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement, allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure. Event times were the scheduled week of the initial failing measurement (RNA scheduled at week 0, 12, 24, 48 and every 24 weeks after). Censoring times were the scheduled week of the last RNA result. A new resistance-associated mutation is defined as one not present in the genotype prior to entry.', 'unitOfMeasure': 'weeks', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'categories': [{'measurements': [{'value': '20', 'groupId': 'OG000'}, {'value': '32', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From week 24 through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure\\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry (to allow for 14 day window for scheduling the visit).HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement, allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure. A new resistance-associated mutation is defined as one not present in the genotype prior to entry.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Percent of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing, by Week 48 [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'categories': [{'measurements': [{'value': '7.8', 'groupId': 'OG000', 'lowerLimit': '4.9', 'upperLimit': '11.7'}, {'value': '12.1', 'groupId': 'OG001', 'lowerLimit': '8.4', 'upperLimit': '16.6'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From week 24 to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure\\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry(to allow for 14 day window for scheduling the visit).HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement,allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure.Event times were the scheduled week of the initial failing measurement(RNA scheduled at week 0, 12, 24, 48 and every 24 weeks after).Censoring times were the scheduled week of the last RNA result.A new resistance-associated mutation is defined as one not present in the genotype prior to entry.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Time From Study Entry/Randomization to Death [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'title': '1st percentile', 'categories': [{'measurements': [{'value': '11.3', 'groupId': 'OG000', 'lowerLimit': '3.1', 'upperLimit': '27.4'}, {'value': '15.9', 'groupId': 'OG001', 'lowerLimit': '2.4', 'upperLimit': '51.4'}]}]}, {'title': '5th percentile', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG000', 'lowerLimit': '27.4', 'upperLimit': 'NA'}, {'value': '82.1', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG001', 'lowerLimit': '51.4', 'upperLimit': 'NA'}]}]}, {'title': '10th percentile', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 90%', 'groupId': 'OG001', 'lowerLimit': '110.1', 'upperLimit': 'NA'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Event time was the exact week of death. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit.', 'unitOfMeasure': 'weeks', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Percent of Participants Experiencing Death by Week 48 [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'categories': [{'measurements': [{'value': '3.9', 'groupId': 'OG000', 'lowerLimit': '2.0', 'upperLimit': '6.8'}, {'value': '1.5', 'groupId': 'OG001', 'lowerLimit': '0.5', 'upperLimit': '3.6'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Event time was the exact week of death. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Time From Study Entry/Randomization to the First of Death, an AIDS-defining Event or a Non-AIDS-defining Event [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'title': '1st percentile', 'categories': [{'measurements': [{'value': '4.0', 'groupId': 'OG000', 'lowerLimit': '3.1', 'upperLimit': '4.0'}, {'value': '4.0', 'groupId': 'OG001', 'lowerLimit': '2.4', 'upperLimit': '12.0'}]}]}, {'title': '5th percentile', 'categories': [{'measurements': [{'value': '27.6', 'groupId': 'OG000', 'lowerLimit': '4.0', 'upperLimit': '42.9'}, {'value': '42.3', 'groupId': 'OG001', 'lowerLimit': '12.4', 'upperLimit': '58.9'}]}]}, {'title': '10th percentile', 'categories': [{'measurements': [{'value': '60.6', 'groupId': 'OG000', 'lowerLimit': '36.0', 'upperLimit': '84.0'}, {'value': '77.9', 'groupId': 'OG001', 'lowerLimit': '48.0', 'upperLimit': '91.6'}]}]}, {'title': '25th percentile', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG000', 'lowerLimit': '142.4', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG001', 'lowerLimit': '112.7', 'upperLimit': 'NA'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Event time was the exact week of death, AIDS-defining event or non-AIDS defining event. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit. Only new events were considered, an event that was also reported at or prior to study entry was not included. If a participant experienced multiple events, then the time of the first event was used in the analysis. AIDS defining events included parasitic, fungal, bacterial, and viral infections as well as neoplastic diseases, and neurological disorders. Non-AIDS defining events included malignancies, diabetes, neuropathies, cardiac and renal events.', 'unitOfMeasure': 'weeks', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Percent of Participants Experiencing Death, AIDS-defining Event or a Non-AIDS-defining Event by Week 48 [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'categories': [{'measurements': [{'value': '8.2', 'groupId': 'OG000', 'lowerLimit': '5.3', 'upperLimit': '12.0'}, {'value': '6.5', 'groupId': 'OG001', 'lowerLimit': '3.9', 'upperLimit': '9.9'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Event time was the exact week of death, AIDS-defining event or non-AIDS defining event. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit. Only new events were considered, an event that was also reported at or prior to study entry was not included. If a participant experienced multiple events, then the time of the first event was used in the analysis. AIDS defining events included parasitic, fungal, bacterial, and viral infections as well as neoplastic diseases, and neurological disorders. Non-AIDS defining events included malignancies, diabetes, neuropathies, cardiac and renal events.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Time From Study Entry/Randomization to the First of Death or Hospitalization [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'title': '1st percentile', 'categories': [{'measurements': [{'value': '2.3', 'groupId': 'OG000', 'lowerLimit': '2.0', 'upperLimit': '4.0'}, {'value': '2.3', 'groupId': 'OG001', 'lowerLimit': '1.0', 'upperLimit': '5.6'}]}]}, {'title': '5th percentile', 'categories': [{'measurements': [{'value': '11.3', 'groupId': 'OG000', 'lowerLimit': '4.0', 'upperLimit': '25.1'}, {'value': '20.3', 'groupId': 'OG001', 'lowerLimit': '8.7', 'upperLimit': '32.4'}]}]}, {'title': '10th percentile', 'categories': [{'measurements': [{'value': '44.6', 'groupId': 'OG000', 'lowerLimit': '20.6', 'upperLimit': '90.7'}, {'value': '45.3', 'groupId': 'OG001', 'lowerLimit': '25.6', 'upperLimit': '77.9'}]}]}, {'title': '25th percentile', 'categories': [{'measurements': [{'value': '168.9', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG000', 'lowerLimit': '119.6', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG001', 'lowerLimit': '107.3', 'upperLimit': 'NA'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Event time was the exact week of death or hospitalization. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit. If a participant experienced multiple events, then the time of the first event was used in the analysis.', 'unitOfMeasure': 'weeks', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Percent of Participants With Death or Hospitalization by Week 48 [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'categories': [{'measurements': [{'value': '10.6', 'groupId': 'OG000', 'lowerLimit': '7.2', 'upperLimit': '14.7'}, {'value': '10.6', 'groupId': 'OG001', 'lowerLimit': '7.3', 'upperLimit': '14.7'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Event time was the exact week of death or hospitalization. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit. If a participant experienced multiple events, then the time of the first event was used in the analysis.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Time From Study Entry/Randomization to Treatment Modification or Discontinuation [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'title': '1st percentile', 'categories': [{'measurements': [{'value': '1.0', 'groupId': 'OG000', 'lowerLimit': '0.0', 'upperLimit': '3.7'}, {'value': '2.4', 'groupId': 'OG001', 'lowerLimit': '0.1', 'upperLimit': '5.9'}]}]}, {'title': '5th percentile', 'categories': [{'measurements': [{'value': '5.1', 'groupId': 'OG000', 'lowerLimit': '3.7', 'upperLimit': '9.3'}, {'value': '22.3', 'groupId': 'OG001', 'lowerLimit': '9.0', 'upperLimit': '31.9'}]}]}, {'title': '10th percentile', 'categories': [{'measurements': [{'value': '23.6', 'groupId': 'OG000', 'lowerLimit': '6.9', 'upperLimit': '36.0'}, {'value': '38.9', 'groupId': 'OG001', 'lowerLimit': '26.0', 'upperLimit': '47.0'}]}]}, {'title': '25th percentile', 'categories': [{'measurements': [{'value': '84.0', 'groupId': 'OG000', 'lowerLimit': '48.7', 'upperLimit': '148.3'}, {'value': '111.1', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 75%', 'groupId': 'OG001', 'lowerLimit': '72.4', 'upperLimit': 'NA'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Treatment modification is defined as the first occurrence of a substitution or subtraction of one or more drugs in the study regimen, a temporary hold lasting 7 days or longer, or the addition of a new drug to the regimen. This would not include splitting any fixed dose combination medications if the participant continues on the active drugs of the combination. Event time was the exact week of the modification or discontinuation. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit.', 'unitOfMeasure': 'weeks', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Percent of Participants With Treatment Modification or Discontinuation by Week 48 [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'categories': [{'measurements': [{'value': '19.1', 'groupId': 'OG000', 'lowerLimit': '14.5', 'upperLimit': '24.1'}, {'value': '13.6', 'groupId': 'OG001', 'lowerLimit': '9.8', 'upperLimit': '18.1'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Treatment modification is defined as the first occurrence of a substitution or subtraction of one or more drugs in the study regimen, a temporary hold lasting 7 days or longer, or the addition of a new drug to the regimen. This would not include splitting any fixed dose combination medications if the participant continues on the active drugs of the combination. Event time was the exact week of the modification or discontinuation. Censoring time was the earliest time point between last dose week and the week of the last step 1/2 visit.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Time From Study Entry/Randomization to Treatment Modification or Discontinuation Due to Toxicity [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'title': '1st percentile', 'categories': [{'measurements': [{'value': '3.1', 'groupId': 'OG000', 'lowerLimit': '0.4', 'upperLimit': '5.0'}, {'value': '9.0', 'groupId': 'OG001', 'lowerLimit': '0.1', 'upperLimit': '41.0'}]}]}, {'title': '5th percentile', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG000', 'lowerLimit': '5.0', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG001', 'lowerLimit': '41.0', 'upperLimit': 'NA'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Treatment modification is defined as the first occurrence of a substitution or subtraction of one or more drugs in the study regimen, a temporary hold lasting 7 days or longer, or the addition of a new drug to the regimen, due to an adverse event. This would not include splitting any fixed dose combination medications if the participant continues on the active drugs of the combination. Event time was the exact week of the modification or discontinuation. Censoring time was the earliest time point between last dose week and the week of the last step 1/2 visit. DAIDS AE Grading Table, Version 1.0 was used.', 'unitOfMeasure': 'weeks', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Percent of Participants With Treatment Modification or Discontinuation Due to Toxicity by Week 48 [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.8', 'groupId': 'OG000', 'lowerLimit': '1.2', 'upperLimit': '5.3'}, {'value': '2.3', 'groupId': 'OG001', 'lowerLimit': '1.0', 'upperLimit': '4.7'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Treatment modification is defined as the first occurrence of a substitution or subtraction of one or more drugs in the study regimen, a temporary hold lasting 7 days or longer, or the addition of a new drug to the regimen, due to an adverse event. This would not include splitting any fixed dose combination medications if the participant continues on the active drugs of the combination. Event time was the exact week of the modification or discontinuation. Censoring time was the earliest time point between last dose week and the week of the last step 1/2 visit. DAIDS AE Grading Table, Version 1.0 was used.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Time From Study Entry/Randomization to the Development of Immune Reconstitution Inflammatory Syndrome (IRIS) [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'title': '1st percentile', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG000', 'lowerLimit': '9.0', 'upperLimit': 'NA'}, {'value': '25.0', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 99%', 'groupId': 'OG001', 'lowerLimit': '13.0', 'upperLimit': 'NA'}]}]}, {'title': '5th percentile', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Event time was the exact week of the diagnosis. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit.', 'unitOfMeasure': 'weeks', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Percent of Participants That Developed Immune Reconstitution Inflammatory Syndrome (IRIS) by Week 48 [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.4', 'groupId': 'OG000', 'lowerLimit': '.03', 'upperLimit': '2.1'}, {'value': '1.1', 'groupId': 'OG001', 'lowerLimit': '0.3', 'upperLimit': '3.1'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Event time was the exact week of the diagnosis. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Time to First Dose Modification Due to Grade 3 or 4 Toxicity [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'title': '1st percentile', 'categories': [{'measurements': [{'value': '45.7', 'comment': 'Not estimable as the upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG000', 'lowerLimit': '5.9', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG001', 'lowerLimit': '63.3', 'upperLimit': 'NA'}]}]}, {'title': '5th percentile', 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Not estimable as the estimate, lower limit and upper limit for the survival function at all weeks is above 95%', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Event time was the exact week of the modification. Censoring time was the earliest time point between last dose week and the week of the last step 1/2 visit. DAIDS AE Grading Table, Version 1.0 was used.', 'unitOfMeasure': 'weeks', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Percent of Participants With a Dose Modification Due to Grade 3 or 4 Toxicity by Week 48 [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.2', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '3.2'}, {'value': '0', 'comment': 'Not estimated due to lack of events in group by week 48', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Event time was the exact week of the modification. Censoring time was the earliest time point between last dose week and the week of the last step 1/2 visit. DAIDS AE Grading Table, Version 1.0 was used.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in CD4+ T-cell Count [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'title': 'Change from baseline at week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '241', 'groupId': 'OG000'}, {'value': '254', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '72', 'spread': '125', 'groupId': 'OG000'}, {'value': '74', 'spread': '118', 'groupId': 'OG001'}]}]}, {'title': 'Change from baseline at week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '235', 'groupId': 'OG000'}, {'value': '247', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '112', 'spread': '162', 'groupId': 'OG000'}, {'value': '107', 'spread': '157', 'groupId': 'OG001'}]}]}, {'title': 'Change from baseline at week 72', 'denoms': [{'units': 'Participants', 'counts': [{'value': '193', 'groupId': 'OG000'}, {'value': '199', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '145', 'spread': '195', 'groupId': 'OG000'}, {'value': '134', 'spread': '170', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, week 24, 48, and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen.', 'unitOfMeasure': 'cells/mm^3', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC with results available at baseline and at the given follow-up time point'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Fasting Values of Total Cholesterol [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'title': 'Change from baseline at week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '183', 'groupId': 'OG000'}, {'value': '183', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '10.1', 'spread': '37.4', 'groupId': 'OG000'}, {'value': '14.4', 'spread': '38.8', 'groupId': 'OG001'}]}]}, {'title': 'Change from baseline at week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '181', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '15.1', 'spread': '39.1', 'groupId': 'OG000'}, {'value': '14.1', 'spread': '40.6', 'groupId': 'OG001'}]}]}, {'title': 'Change from baseline at week 72', 'denoms': [{'units': 'Participants', 'counts': [{'value': '145', 'groupId': 'OG000'}, {'value': '144', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '17.4', 'spread': '41.8', 'groupId': 'OG000'}, {'value': '18.7', 'spread': '40.2', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, week 24, 48, and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen.', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC with results available at baseline and at the given follow-up time point'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Fasting Values of High-density Lipoprotein Cholesterol [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'title': 'Change from baseline at week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '174', 'groupId': 'OG000'}, {'value': '175', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.9', 'spread': '13.0', 'groupId': 'OG000'}, {'value': '3.6', 'spread': '16.1', 'groupId': 'OG001'}]}]}, {'title': 'Change from baseline at week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '176', 'groupId': 'OG000'}, {'value': '179', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '5.6', 'spread': '12.6', 'groupId': 'OG000'}, {'value': '3.7', 'spread': '14.3', 'groupId': 'OG001'}]}]}, {'title': 'Change from baseline at week 72', 'denoms': [{'units': 'Participants', 'counts': [{'value': '141', 'groupId': 'OG000'}, {'value': '139', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.0', 'spread': '13.7', 'groupId': 'OG000'}, {'value': '6.6', 'spread': '14.7', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, week 24, 48, and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen.', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC with results available at baseline and at the given follow-up time point'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Fasting Values of Calculated Low-density Lipoprotein Cholesterol [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'title': 'Change from baseline at week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '178', 'groupId': 'OG000'}, {'value': '181', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '5.5', 'spread': '29.9', 'groupId': 'OG000'}, {'value': '9.5', 'spread': '27.0', 'groupId': 'OG001'}]}]}, {'title': 'Change from baseline at week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '176', 'groupId': 'OG000'}, {'value': '176', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '12.0', 'spread': '31.9', 'groupId': 'OG000'}, {'value': '10.1', 'spread': '30.0', 'groupId': 'OG001'}]}]}, {'title': 'Change from baseline at week 72', 'denoms': [{'units': 'Participants', 'counts': [{'value': '142', 'groupId': 'OG000'}, {'value': '138', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '11.9', 'spread': '33.3', 'groupId': 'OG000'}, {'value': '12.8', 'spread': '31.2', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, week 24, 48, and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen.', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC with results available at baseline and at the given follow-up time point'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Fasting Values of Triglycerides [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'title': 'Change from baseline at week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '177', 'groupId': 'OG000'}, {'value': '180', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '15.3', 'spread': '86.9', 'groupId': 'OG000'}, {'value': '18.7', 'spread': '80.4', 'groupId': 'OG001'}]}]}, {'title': 'Change from baseline at week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '178', 'groupId': 'OG000'}, {'value': '175', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.2', 'spread': '89.4', 'groupId': 'OG000'}, {'value': '19.6', 'spread': '81.1', 'groupId': 'OG001'}]}]}, {'title': 'Change from baseline at week 72', 'denoms': [{'units': 'Participants', 'counts': [{'value': '144', 'groupId': 'OG000'}, {'value': '140', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '13.7', 'spread': '103.4', 'groupId': 'OG000'}, {'value': '7.1', 'spread': '73.7', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, week 24, 48, and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen.', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC with results available at baseline and at the given follow-up time point'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Fasting Values of Glucose [CPI+SOC v SOC]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '257', 'groupId': 'OG000'}, {'value': '264', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'OG001', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'classes': [{'title': 'Change from baseline at week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '178', 'groupId': 'OG000'}, {'value': '184', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.7', 'spread': '26.1', 'groupId': 'OG000'}, {'value': '3.7', 'spread': '18.2', 'groupId': 'OG001'}]}]}, {'title': 'Change from baseline at week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '172', 'groupId': 'OG000'}, {'value': '185', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.6', 'spread': '16.5', 'groupId': 'OG000'}, {'value': '5.1', 'spread': '23.1', 'groupId': 'OG001'}]}]}, {'title': 'Change from baseline at week 72', 'denoms': [{'units': 'Participants', 'counts': [{'value': '141', 'groupId': 'OG000'}, {'value': '148', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.6', 'spread': '29.0', 'groupId': 'OG000'}, {'value': '1.5', 'spread': '45.9', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, week 24, 48, and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen.', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All participants randomized to either CPI+SOC or SOC with results available at baseline and at the given follow-up time point'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'FG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'FG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'FG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'FG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'FG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}, {'id': 'FG006', 'title': 'Cell Phone Intervention (CPI) + Standard of Care (SOC)', 'description': 'The CPI was a simple interactive system (Short Message Service \\[SMS\\] Reminder and Flashback System) to identify non-adherence soon after it occurred and, in response, a site-based culturally relevant algorithm for managing barriers to adherence. Reminders were sent daily for the first 8 weeks on study, then three times per week for the next 8 weeks, and then weekly through to 48 weeks after study entry. Participants were expected to respond ("flashback") to each reminder. Failure to respond, triggered the system to alert the site to contact the participant. Sites were instructed to contact the participant if they missed any three flashbacks over two weeks during the daily messaging period, any two missed flashbacks over two weeks of the three times a week messaging period, and any two missed flashbacks over two weeks during the weekly messaging period. Additionally, sites were instructed to continue the local standard of care practices for managing adherence barriers.'}, {'id': 'FG007', 'title': 'Standard of Care (SOC)', 'description': 'Sites were instructed to continue the local standard of care practices for managing adherence barriers.'}], 'periods': [{'title': 'Cohorts', 'milestones': [{'type': 'STARTED', 'comment': 'Participants were followed on step 1/2 until 48 weeks after the last participant enrolled to Step 1.', 'achievements': [{'groupId': 'FG000', 'numSubjects': '287'}, {'groupId': 'FG001', 'numSubjects': '74'}, {'groupId': 'FG002', 'numSubjects': '72'}, {'groupId': 'FG003', 'numSubjects': '8'}, {'groupId': 'FG004', 'numSubjects': '70'}, {'groupId': 'FG005', 'numSubjects': '34'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}, {'type': 'Followed 72 Weeks on Step 1/2', 'achievements': [{'groupId': 'FG000', 'numSubjects': '211'}, {'groupId': 'FG001', 'numSubjects': '60'}, {'groupId': 'FG002', 'numSubjects': '60'}, {'groupId': 'FG003', 'numSubjects': '6'}, {'groupId': 'FG004', 'numSubjects': '52'}, {'groupId': 'FG005', 'numSubjects': '30'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'comment': 'Completed the study = participant must have had the last step 1/2 visit between 22NOV2016-13FEB2017', 'achievements': [{'groupId': 'FG000', 'numSubjects': '253'}, {'groupId': 'FG001', 'numSubjects': '73'}, {'groupId': 'FG002', 'numSubjects': '68'}, {'groupId': 'FG003', 'numSubjects': '8'}, {'groupId': 'FG004', 'numSubjects': '67'}, {'groupId': 'FG005', 'numSubjects': '33'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '34'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '3'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '18'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '16'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}]}, {'title': 'Randomized Adherence Intervention', 'milestones': [{'type': 'STARTED', 'comment': 'Participants were followed on step 1/2 until 48 weeks after the last participant enrolled to Step 1.', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '257'}, {'groupId': 'FG007', 'numSubjects': '264'}]}, {'type': 'Followed 72 Weeks on Step 1/2', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '196'}, {'groupId': 'FG007', 'numSubjects': '202'}]}, {'type': 'COMPLETED', 'comment': 'Completed the study = participant must have had the last step 1/2 visit between 22NOV2016-13FEB2017', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '238'}, {'groupId': 'FG007', 'numSubjects': '240'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '19'}, {'groupId': 'FG007', 'numSubjects': '24'}]}], 'dropWithdraws': [{'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '11'}, {'groupId': 'FG007', 'numSubjects': '12'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '8'}, {'groupId': 'FG007', 'numSubjects': '12'}]}]}], 'recruitmentDetails': 'Participants were enrolled between 22FEB2013 and 21DEC2015 at non-US based clinical research sites.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '287', 'groupId': 'BG000'}, {'value': '74', 'groupId': 'BG001'}, {'value': '72', 'groupId': 'BG002'}, {'value': '8', 'groupId': 'BG003'}, {'value': '70', 'groupId': 'BG004'}, {'value': '34', 'groupId': 'BG005'}, {'value': '545', 'groupId': 'BG006'}]}], 'groups': [{'id': 'BG000', 'title': 'Experimental: Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure • Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.'}, {'id': 'BG001', 'title': 'Experimental: Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV'}, {'id': 'BG002', 'title': 'Experimental: Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening • ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV'}, {'id': 'BG003', 'title': 'Experimental: Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening • RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC'}, {'id': 'BG004', 'title': 'Experimental: Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV) • Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV'}, {'id': 'BG005', 'title': 'Experimental: Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs'}, {'id': 'BG006', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '40', 'spread': '11', 'groupId': 'BG000'}, {'value': '42', 'spread': '10', 'groupId': 'BG001'}, {'value': '42', 'spread': '9', 'groupId': 'BG002'}, {'value': '40', 'spread': '10', 'groupId': 'BG003'}, {'value': '42', 'spread': '10', 'groupId': 'BG004'}, {'value': '42', 'spread': '10', 'groupId': 'BG005'}, {'value': '41', 'spread': '10', 'groupId': 'BG006'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '160', 'groupId': 'BG000'}, {'value': '29', 'groupId': 'BG001'}, {'value': '28', 'groupId': 'BG002'}, {'value': '4', 'groupId': 'BG003'}, {'value': '23', 'groupId': 'BG004'}, {'value': '14', 'groupId': 'BG005'}, {'value': '258', 'groupId': 'BG006'}]}, {'title': 'Male', 'measurements': [{'value': '127', 'groupId': 'BG000'}, {'value': '45', 'groupId': 'BG001'}, {'value': '44', 'groupId': 'BG002'}, {'value': '4', 'groupId': 'BG003'}, {'value': '47', 'groupId': 'BG004'}, {'value': '20', 'groupId': 'BG005'}, {'value': '287', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '38', 'groupId': 'BG000'}, {'value': '7', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '8', 'groupId': 'BG005'}, {'value': '63', 'groupId': 'BG006'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '241', 'groupId': 'BG000'}, {'value': '62', 'groupId': 'BG001'}, {'value': '59', 'groupId': 'BG002'}, {'value': '8', 'groupId': 'BG003'}, {'value': '60', 'groupId': 'BG004'}, {'value': '24', 'groupId': 'BG005'}, {'value': '454', 'groupId': 'BG006'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '8', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '9', 'groupId': 'BG004'}, {'value': '2', 'groupId': 'BG005'}, {'value': '28', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}]}, {'title': 'Asian', 'measurements': [{'value': '62', 'groupId': 'BG000'}, {'value': '21', 'groupId': 'BG001'}, {'value': '17', 'groupId': 'BG002'}, {'value': '3', 'groupId': 'BG003'}, {'value': '35', 'groupId': 'BG004'}, {'value': '8', 'groupId': 'BG005'}, {'value': '146', 'groupId': 'BG006'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}]}, {'title': 'Black or African American', 'measurements': [{'value': '195', 'groupId': 'BG000'}, {'value': '49', 'groupId': 'BG001'}, {'value': '49', 'groupId': 'BG002'}, {'value': '5', 'groupId': 'BG003'}, {'value': '34', 'groupId': 'BG004'}, {'value': '21', 'groupId': 'BG005'}, {'value': '353', 'groupId': 'BG006'}]}, {'title': 'White', 'measurements': [{'value': '7', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '3', 'groupId': 'BG005'}, {'value': '14', 'groupId': 'BG006'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '1', 'groupId': 'BG006'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '23', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '31', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'Brazil', 'categories': [{'measurements': [{'value': '25', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '8', 'groupId': 'BG005'}, {'value': '49', 'groupId': 'BG006'}]}]}, {'title': 'Haiti', 'categories': [{'measurements': [{'value': '34', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '45', 'groupId': 'BG006'}]}]}, {'title': 'India', 'categories': [{'measurements': [{'value': '55', 'groupId': 'BG000'}, {'value': '18', 'groupId': 'BG001'}, {'value': '16', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '32', 'groupId': 'BG004'}, {'value': '5', 'groupId': 'BG005'}, {'value': '128', 'groupId': 'BG006'}]}]}, {'title': 'Kenya', 'categories': [{'measurements': [{'value': '32', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '7', 'groupId': 'BG004'}, {'value': '2', 'groupId': 'BG005'}, {'value': '59', 'groupId': 'BG006'}]}]}, {'title': 'Malawi', 'categories': [{'measurements': [{'value': '18', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '9', 'groupId': 'BG004'}, {'value': '2', 'groupId': 'BG005'}, {'value': '37', 'groupId': 'BG006'}]}]}, {'title': 'Peru', 'categories': [{'measurements': [{'value': '18', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '22', 'groupId': 'BG006'}]}]}, {'title': 'South Africa', 'categories': [{'measurements': [{'value': '58', 'groupId': 'BG000'}, {'value': '7', 'groupId': 'BG001'}, {'value': '11', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '7', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '84', 'groupId': 'BG006'}]}]}, {'title': 'Thailand', 'categories': [{'measurements': [{'value': '7', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '3', 'groupId': 'BG005'}, {'value': '18', 'groupId': 'BG006'}]}]}, {'title': 'Uganda', 'categories': [{'measurements': [{'value': '34', 'groupId': 'BG000'}, {'value': '13', 'groupId': 'BG001'}, {'value': '17', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '6', 'groupId': 'BG004'}, {'value': '9', 'groupId': 'BG005'}, {'value': '81', 'groupId': 'BG006'}]}]}, {'title': 'Zimbabwe', 'categories': [{'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '4', 'groupId': 'BG005'}, {'value': '22', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Plasma HIV-1 RNA, categorical', 'classes': [{'categories': [{'title': '< 40 copies/mL', 'measurements': [{'value': '11', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '12', 'groupId': 'BG006'}]}, {'title': '40 - < 200 copies/mL', 'measurements': [{'value': '11', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '18', 'groupId': 'BG006'}]}, {'title': '200 - < 1000 copies/mL', 'measurements': [{'value': '32', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '9', 'groupId': 'BG004'}, {'value': '2', 'groupId': 'BG005'}, {'value': '52', 'groupId': 'BG006'}]}, {'title': '1000 - < 10,000 copies/mL', 'measurements': [{'value': '59', 'groupId': 'BG000'}, {'value': '17', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}, {'value': '3', 'groupId': 'BG003'}, {'value': '12', 'groupId': 'BG004'}, {'value': '10', 'groupId': 'BG005'}, {'value': '121', 'groupId': 'BG006'}]}, {'title': '10,000 - < 100,000 copies/mL', 'measurements': [{'value': '106', 'groupId': 'BG000'}, {'value': '21', 'groupId': 'BG001'}, {'value': '18', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '20', 'groupId': 'BG004'}, {'value': '9', 'groupId': 'BG005'}, {'value': '175', 'groupId': 'BG006'}]}, {'title': '100,000 - < 1,000,000 copies/mL', 'measurements': [{'value': '60', 'groupId': 'BG000'}, {'value': '27', 'groupId': 'BG001'}, {'value': '25', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '22', 'groupId': 'BG004'}, {'value': '10', 'groupId': 'BG005'}, {'value': '146', 'groupId': 'BG006'}]}, {'title': '1,000,000 - < 10,000,000 copies/mL', 'measurements': [{'value': '8', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '5', 'groupId': 'BG004'}, {'value': '2', 'groupId': 'BG005'}, {'value': '20', 'groupId': 'BG006'}]}, {'title': '>= 10,000,000 copies/mL', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '1', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': 'Baseline Plasma HIV-1 RNA is defined as the last available result on or before the date of study entry', 'unitOfMeasure': 'Participants'}, {'title': 'CD4+ T-Cell Count, categorical', 'classes': [{'categories': [{'title': '< 50 cells/mm^3', 'measurements': [{'value': '50', 'groupId': 'BG000'}, {'value': '17', 'groupId': 'BG001'}, {'value': '11', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '9', 'groupId': 'BG004'}, {'value': '7', 'groupId': 'BG005'}, {'value': '95', 'groupId': 'BG006'}]}, {'title': '50 - < 200 cells/mm^3', 'measurements': [{'value': '108', 'groupId': 'BG000'}, {'value': '27', 'groupId': 'BG001'}, {'value': '25', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '31', 'groupId': 'BG004'}, {'value': '10', 'groupId': 'BG005'}, {'value': '202', 'groupId': 'BG006'}]}, {'title': '200 - < 350 cells/mm^3', 'measurements': [{'value': '79', 'groupId': 'BG000'}, {'value': '15', 'groupId': 'BG001'}, {'value': '23', 'groupId': 'BG002'}, {'value': '5', 'groupId': 'BG003'}, {'value': '19', 'groupId': 'BG004'}, {'value': '7', 'groupId': 'BG005'}, {'value': '148', 'groupId': 'BG006'}]}, {'title': '350 - < 500 cells/mm^3', 'measurements': [{'value': '30', 'groupId': 'BG000'}, {'value': '12', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '6', 'groupId': 'BG004'}, {'value': '8', 'groupId': 'BG005'}, {'value': '63', 'groupId': 'BG006'}]}, {'title': '>= 500 cells/mm^3', 'measurements': [{'value': '20', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '5', 'groupId': 'BG004'}, {'value': '2', 'groupId': 'BG005'}, {'value': '37', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': 'Baseline CD4+ T-cell count is defined as the last available result on or before the date of study entry', 'unitOfMeasure': 'Participants'}, {'title': 'IV drug history, categorical', 'classes': [{'categories': [{'title': 'Never', 'measurements': [{'value': '286', 'groupId': 'BG000'}, {'value': '74', 'groupId': 'BG001'}, {'value': '72', 'groupId': 'BG002'}, {'value': '8', 'groupId': 'BG003'}, {'value': '70', 'groupId': 'BG004'}, {'value': '34', 'groupId': 'BG005'}, {'value': '544', 'groupId': 'BG006'}]}, {'title': 'Previously', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '1', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Hepatitis B Surface Antigen Result, categorical', 'classes': [{'categories': [{'title': 'Positive', 'measurements': [{'value': '14', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '8', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '4', 'groupId': 'BG005'}, {'value': '29', 'groupId': 'BG006'}]}, {'title': 'Negative', 'measurements': [{'value': '273', 'groupId': 'BG000'}, {'value': '74', 'groupId': 'BG001'}, {'value': '72', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '66', 'groupId': 'BG004'}, {'value': '30', 'groupId': 'BG005'}, {'value': '515', 'groupId': 'BG006'}]}, {'title': 'Indeterminate', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '1', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'All enrolled participants.'}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 545}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2013-02-22', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-03', 'completionDateStruct': {'date': '2018-12-31', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-03-14', 'studyFirstSubmitDate': '2012-06-28', 'resultsFirstSubmitDate': '2017-11-20', 'studyFirstSubmitQcDate': '2012-07-12', 'lastUpdatePostDateStruct': {'date': '2019-03-15', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2018-01-22', 'studyFirstPostDateStruct': {'date': '2012-07-16', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2018-02-20', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2016-11-23', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 48 Weeks', 'timeFrame': '48 weeks after the date of entry', 'description': 'The measurement closest to exactly 48 weeks (ie, 7x48=336 days) after the date of entry, within the window of 48 weeks ± 6 weeks (specifically 295 to 378 days after randomization, inclusive).\n\nThe analysis in the protocol and in the Stat. Analysis Plan involved estimating the proportion of participants in the overall study population with HIV-1 RNA ≤200 copies/mL at week 48 with a 95% confidence interval calculated via a Wald approach. Death or lost to follow-up before week 48 was considered as HIV-1 RNA\\>200 copies/mL at week 48. Missing results at week 48 were considered as HIV-1 RNA \\>200 copies/mL at week 48 unless the immediately preceding and succeeding HIV-1 RNA measurements were ≤200 copies/mL. Since the primary analysis was on the total study population, overall results were also submitted. All participants in B3 had HIV-1 RNA ≤200 copies/mL at week 48. Therefore, Wald confidence interval could not be computed for B3 and Clopper-Pearson Exact confidence interval is provided.'}], 'secondaryOutcomes': [{'measure': 'Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 24 Weeks', 'timeFrame': '24 weeks after the date of entry', 'description': 'The measurement closest to exactly 24 weeks (ie, 7x24=168 days) after the date of entry, within the window of 24 weeks ± 6 weeks (specifically 127 to 210 days after randomization, inclusive).\n\nThe analysis in the protocol and in the Stat. Analysis Plan involved estimating the proportion of participants in the overall study population with HIV-1 RNA ≤200 copies/mL at week 24 with a 95% confidence interval calculated via a Wald approach. Death or lost to follow-up before week 24 was considered as HIV-1 RNA\\>200 copies/mL at week 24. Missing results at week 24 were considered as HIV-1 RNA \\>200 copies/mL at week 24 unless the immediately preceding and succeeding HIV-1 RNA measurements were ≤200 copies/mL. Since the primary analysis was on the total study population, overall results were also submitted. All participants in B3 had HIV-1 RNA ≤200 copies/mL at week 24. Therefore, Wald confidence interval could not be computed for B3 and Clopper-Pearson Exact confidence interval is provided.'}, {'measure': 'Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 72 Weeks', 'timeFrame': '72 weeks after the date of entry', 'description': 'The measurement closest to exactly 72 weeks (ie, 7x72=504 days) after the date of entry, within the window of 72 weeks ± 6 weeks (specifically 463 to 546 days, inclusive).\n\nThe analysis in the protocol and in the Analysis Plan involved estimating the proportion of participants in the overall study population with HIV-1 RNA ≤200 copies/mL at week 72 with a 95% confidence interval calculated via a Wald approach. Death or lost to follow-up before week 72 was considered as HIV-1 RNA\\>200 copies/mL at week 72. If a result was expected, missing results at week 72 were considered as HIV-1 RNA \\>200 copies/mL at week 72 unless the immediately preceding and succeeding HIV-1 RNA measurements were ≤200 copies/mL. Since the primary analysis was on the total study population, overall results were also submitted. All participants in B3 had HIV-1 RNA ≤200 copies/mL at week 72. Therefore, Wald confidence interval could not be computed for B3 and Clopper-Pearson Exact confidence interval is provided.'}, {'measure': 'Number of Weeks of Follow-up', 'timeFrame': 'From study entry through Step 1/2 follow-up', 'description': 'All participants were followed on step 1/2 until 48 weeks after the last participant was enrolled to step 1 regardless of virologic status or treatment switches. Length of follow-up varied by Cohort.'}, {'measure': 'Time to Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study', 'timeFrame': 'From week 24 through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure \\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry (to allow for 14 day window for scheduling the visit). HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement, allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure. Event times were the scheduled week of the initial failing measurement (RNA scheduled at week 0, 12, 24, 48 and every 24 weeks after). Censoring times were the scheduled week of the last RNA result. Length of follow-up varied by Cohort.'}, {'measure': 'Number of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study', 'timeFrame': 'From week 24 through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure \\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry (to allow for 14 day window for scheduling the visit). HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement, allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure. Length of follow-up varied by Cohort.'}, {'measure': 'Percent of Participants With Confirmed Virologic Failure by Week 48', 'timeFrame': 'From week 24 to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure \\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry(to allow for 14 day window for scheduling the visit). HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement,allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure. Event times were the scheduled week of the initial failing measurement (RNA scheduled at week 0, 12, 24, 48 and every 24 weeks after). Censoring times were the scheduled week of the last RNA result. Length of follow-up varied by Cohort.'}, {'measure': 'Time to Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing', 'timeFrame': 'From week 24 through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure \\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry (to allow for 14 day window for scheduling the visit). HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement, allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure. Event times were the scheduled week of the initial failing measurement (RNA scheduled at week 0, 12, 24, 48 and every 24 weeks after). Censoring times were the scheduled week of the last RNA result. Length of follow-up varied by Cohort. A new resistance-associated mutation is defined as one not present in the genotype prior to entry.'}, {'measure': 'Number of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing', 'timeFrame': 'From week 24 through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure\\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry (to allow for 14 day window for scheduling the visit).HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement, allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure. Length of follow-up varied by Cohort. A new resistance-associated mutation is defined as one not present in the genotype prior to entry.'}, {'measure': 'Percent of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing, by Week 48', 'timeFrame': 'From week 24 to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure\\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry(to allow for 14 day window for scheduling the visit).HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement,allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure.Event times were the scheduled week of the initial failing measurement(RNA scheduled at week 0, 12, 24, 48 and every 24 weeks after).Censoring times were the scheduled week of the last RNA result.Length of follow-up varied by Cohort.A new resistance-associated mutation is defined as one not present in the genotype prior to entry.'}, {'measure': 'Time From Study Entry/Randomization to Death', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Event time was the exact week of death. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit. Length of follow-up varied by Cohort.'}, {'measure': 'Percent of Participants Experiencing Death by Week 48', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Event time was the exact week of death. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit.'}, {'measure': 'Time From Study Entry/Randomization to the First of Death, an AIDS-defining Event or a Non-AIDS-defining Event', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Event time was the exact week of death, AIDS-defining event or non-AIDS defining event. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit. Only new events were considered, an event that was also reported at or prior to study entry was not included. If a participant experienced multiple events, then the time of the first event was used in the analysis. AIDS defining events included parasitic, fungal, bacterial, and viral infections as well as neoplastic diseases, and neurological disorders. Non-AIDS defining events included malignancies, diabetes, neuropathies, cardiac and renal events. Length of follow-up varied by Cohort.'}, {'measure': 'Percent of Participants Experiencing Death, AIDS-defining Event or a Non-AIDS-defining Event by Week 48', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Event time was the exact week of death, AIDS-defining event or non-AIDS defining event. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit. Only new events were considered, an event that was also reported at or prior to study entry was not included. If a participant experienced multiple events, then the time of the first event was used in the analysis. AIDS defining events included parasitic, fungal, bacterial, and viral infections as well as neoplastic diseases, and neurological disorders. Non-AIDS defining events included malignancies, diabetes, neuropathies, cardiac and renal events.'}, {'measure': 'Time From Study Entry/Randomization to the First of Death or Hospitalization.', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Event time was the exact week of death or hospitalization. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit. If a participant experienced multiple events, then the time of the first event was used in the analysis. Length of follow-up varied by Cohort.'}, {'measure': 'Percent of Participants With Death or Hospitalization by Week 48', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Event time was the exact week of death or hospitalization. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit. If a participant experienced multiple events, then the time of the first event was used in the analysis.'}, {'measure': 'Time From Study Entry/Randomization to Treatment Modification or Discontinuation.', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Treatment modification is defined as the first occurrence of a substitution or subtraction of one or more drugs in the study regimen, a temporary hold lasting 7 days or longer, or the addition of a new drug to the regimen. This would not include splitting any fixed dose combination medications if the participant continues on the active drugs of the combination. Event time was the exact week of the modification or discontinuation. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit. Length of follow-up varied by Cohort.'}, {'measure': 'Percent of Participants With Treatment Modification or Discontinuation by Week 48', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Treatment modification is defined as the first occurrence of a substitution or subtraction of one or more drugs in the study regimen, a temporary hold lasting 7 days or longer, or the addition of a new drug to the regimen. This would not include splitting any fixed dose combination medications if the participant continues on the active drugs of the combination. Event time was the exact week of the modification or discontinuation. Censoring time was the earliest time point between last dose week and the week of the last step 1/2 visit.'}, {'measure': 'Time From Study Entry/Randomization to Treatment Modification or Discontinuation Due to Toxicity', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Treatment modification is defined as the first occurrence of a substitution or subtraction of one or more drugs in the study regimen, a temporary hold lasting 7 days or longer, or the addition of a new drug to the regimen, due to an adverse event. This would not include splitting any fixed dose combination medications if the participant continues on the active drugs of the combination. Event time was the exact week of the modification or discontinuation. Censoring time was the earliest time point between last dose week and the week of the last step 1/2 visit. Length of follow-up varied by Cohort. DAIDS AE Grading Table, Version 1.0 was used.'}, {'measure': 'Percent of Participants With Treatment Modification or Discontinuation Due to Toxicity by Week 48', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Treatment modification is defined as the first occurrence of a substitution or subtraction of one or more drugs in the study regimen, a temporary hold lasting 7 days or longer, or the addition of a new drug to the regimen, due to an adverse event. This would not include splitting any fixed dose combination medications if the participant continues on the active drugs of the combination. Event time was the exact week of the modification or discontinuation. Censoring time was the earliest time point between last dose week and the week of the last step 1/2 visit. DAIDS AE Grading Table, Version 1.0 was used.'}, {'measure': 'Time From Study Entry/Randomization to the Development of Immune Reconstitution Inflammatory Syndrome (IRIS)', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Event time was the exact week of the diagnosis. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit. Length of follow-up varied by Cohort.'}, {'measure': 'Percent of Participants That Developed Immune Reconstitution Inflammatory Syndrome (IRIS) by Week 48', 'timeFrame': 'From study entry to week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Event time was the exact week of the diagnosis. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit.'}, {'measure': 'Time to First Dose Modification Due to Grade 3 or 4 Toxicity', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Event time was the exact week of the modification. Censoring time was the earliest time point between last dose week and the week of the last step 1/2 visit. Length of follow-up varied by Cohort. DAIDS AE Grading Table, Version 1.0 was used.'}, {'measure': 'Percent of Participants With a Dose Modification Due to Grade 3 or 4 Toxicity by Week 48', 'timeFrame': 'From study entry to week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Event time was the exact week of the modification. Censoring time was the earliest time point between last dose week and the week of the last step 1/2 visit. DAIDS AE Grading Table, Version 1.0 was used.'}, {'measure': 'Change From Baseline in CD4+ T-cell Count', 'timeFrame': 'Baseline, week 24, 48, and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen (this second date applies only to Cohorts B, C and D as there is no change of regimen for patients in Cohort A)'}, {'measure': 'Change From Baseline in Fasting Values of Total Cholesterol', 'timeFrame': 'Baseline, week 24, 48 and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen (this second date applies only to Cohorts B, C and D as there is no change of regimen for patients in Cohort A)'}, {'measure': 'Change From Baseline in Fasting Values of High-density Lipoprotein Cholesterol', 'timeFrame': 'Baseline, week 24, 48 and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen (this second date applies only to Cohorts B, C and D as there is no change of regimen for patients in Cohort A)\\]'}, {'measure': 'Change From Baseline in Fasting Values of Calculated Low-density Lipoprotein Cholesterol', 'timeFrame': 'Baseline, week 24, 48 and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen (this second date applies only to Cohorts B, C and D as there is no change of regimen for patients in Cohort A)'}, {'measure': 'Change From Baseline in Fasting Values of Triglycerides', 'timeFrame': 'Baseline, week 24, 48 and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen (this second date applies only to Cohorts B, C and D as there is no change of regimen for patients in Cohort A)'}, {'measure': 'Change From Baseline in Fasting Values of Glucose', 'timeFrame': 'Baseline, week 24, 48 and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen (this second date applies only to Cohorts B, C and D as there is no change of regimen for patients in Cohort A)'}, {'measure': 'Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 48 Weeks [CPI+SOC v SOC]', 'timeFrame': '48 weeks after the date of entry', 'description': 'The measurement closest to exactly 48 weeks (ie, 7x48=336 days) after the date of entry, within the window of 48 weeks ± 6 weeks (specifically 295 to 378 days after randomization, inclusive).\n\nThe analysis in the protocol and in the Stat. Analysis Plan involved estimating the proportion of participants in the overall study population with HIV-1 RNA ≤200 copies/mL at week 48 with a 95% confidence interval calculated via a Wald approach. Death or lost to follow-up before week 48 was considered as HIV-1 RNA\\>200 copies/mL at week 48. Missing results at week 48 were considered as HIV-1 RNA \\>200 copies/mL at week 48 unless the immediately preceding and succeeding HIV-1 RNA measurements were ≤200 copies/mL.'}, {'measure': 'Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 24 Weeks [CPI+SOC v SOC]', 'timeFrame': '24 weeks after the date of entry', 'description': 'The measurement closest to exactly 24 weeks (ie, 7x24=168 days) after the date of entry, within the window of 24 weeks ± 6 weeks (specifically 127 to 210 days after randomization, inclusive).\n\nThe analysis in the protocol and in the Stat. Analysis Plan involved estimating the proportion of participants in the overall study population with HIV-1 RNA ≤200 copies/mL at week 24 with a 95% confidence interval calculated via a Wald approach. Death or lost to follow-up before week 24 was considered as HIV-1 RNA\\>200 copies/mL at week 24. Missing results at week 24 were considered as HIV-1 RNA \\>200 copies/mL at week 24 unless the immediately preceding and succeeding HIV-1 RNA measurements were ≤200 copies/mL.'}, {'measure': 'Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 72 Weeks [CPI+SOC v SOC]', 'timeFrame': '72 weeks after the date of entry', 'description': 'The measurement closest to exactly 72 weeks (ie, 7x72=504 days) after the date of entry, within the window of 72 weeks ± 6 weeks (specifically 463 to 546 days, inclusive).\n\nThe analysis in the protocol and in the Analysis Plan involved estimating the proportion of participants in the overall study population with HIV-1 RNA ≤200 copies/mL at week 72 with a 95% confidence interval calculated via a Wald approach. Death or lost to follow-up before week 72 was considered as HIV-1 RNA\\>200 copies/mL at week 72. If a result was expected, missing results at week 72 were considered as HIV-1 RNA \\>200 copies/mL at week 72 unless the immediately preceding and succeeding HIV-1 RNA measurements were ≤200 copies/mL.'}, {'measure': 'Number of Weeks of Follow-up [CPI+SOC v SOC]', 'timeFrame': 'From study entry through Step 1/2 follow-up', 'description': 'All participants were followed on step 1/2 until 48 weeks after the last participant was enrolled to step 1 regardless of virologic status or treatment switches.'}, {'measure': 'Time to Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study [CPI+SOC v SOC]', 'timeFrame': 'From week 24 through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure \\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry (to allow for 14 day window for scheduling the visit). HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement, allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure. Event times were the scheduled week of the initial failing measurement (RNA scheduled at week 0, 12, 24, 48 and every 24 weeks after). Censoring times were the scheduled week of the last RNA result.'}, {'measure': 'Number of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study [CPI+SOC v SOC]', 'timeFrame': 'From week 24 through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure \\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry (to allow for 14 day window for scheduling the visit). HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement, allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure.'}, {'measure': 'Percent of Participants With Confirmed Virologic Failure by Week 48 [CPI+SOC v SOC]', 'timeFrame': 'From week 24 to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure \\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry(to allow for 14 day window for scheduling the visit). HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement,allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure. Event times were the scheduled week of the initial failing measurement (RNA scheduled at week 0, 12, 24, 48 and every 24 weeks after). Censoring times were the scheduled week of the last RNA result.'}, {'measure': 'Time to Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing [CPI+SOC v SOC]', 'timeFrame': 'From week 24 through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure \\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry (to allow for 14 day window for scheduling the visit). HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement, allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure. Event times were the scheduled week of the initial failing measurement (RNA scheduled at week 0, 12, 24, 48 and every 24 weeks after). Censoring times were the scheduled week of the last RNA result. A new resistance-associated mutation is defined as one not present in the genotype prior to entry.'}, {'measure': 'Number of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing [CPI+SOC v SOC]', 'timeFrame': 'From week 24 through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure\\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry (to allow for 14 day window for scheduling the visit).HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement, allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure. A new resistance-associated mutation is defined as one not present in the genotype prior to entry.'}, {'measure': 'Percent of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing, by Week 48 [CPI+SOC v SOC]', 'timeFrame': 'From week 24 to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Virologic failure was confirmed by the next HIV-1 RNA measurement ≥1000 copies/mL (irrespective of time between initial and confirmatory measure\\[specimens on separate dates\\] and treatment status). A week 24 measurement included HIV-1 RNA obtained ≥7\\*22=154 days after study entry(to allow for 14 day window for scheduling the visit).HIV-1 RNA measurements through and including 21 November 2016 were considered in identifying an initial failing measurement,allowing HIV-1 RNA at the close-out visit between 22 November 2016 and 13 February 2017 to be a confirmatory measure.Event times were the scheduled week of the initial failing measurement(RNA scheduled at week 0, 12, 24, 48 and every 24 weeks after).Censoring times were the scheduled week of the last RNA result.A new resistance-associated mutation is defined as one not present in the genotype prior to entry.'}, {'measure': 'Time From Study Entry/Randomization to Death [CPI+SOC v SOC]', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Event time was the exact week of death. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit.'}, {'measure': 'Percent of Participants Experiencing Death by Week 48 [CPI+SOC v SOC]', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Event time was the exact week of death. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit.'}, {'measure': 'Time From Study Entry/Randomization to the First of Death, an AIDS-defining Event or a Non-AIDS-defining Event [CPI+SOC v SOC]', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Event time was the exact week of death, AIDS-defining event or non-AIDS defining event. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit. Only new events were considered, an event that was also reported at or prior to study entry was not included. If a participant experienced multiple events, then the time of the first event was used in the analysis. AIDS defining events included parasitic, fungal, bacterial, and viral infections as well as neoplastic diseases, and neurological disorders. Non-AIDS defining events included malignancies, diabetes, neuropathies, cardiac and renal events.'}, {'measure': 'Percent of Participants Experiencing Death, AIDS-defining Event or a Non-AIDS-defining Event by Week 48 [CPI+SOC v SOC]', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Event time was the exact week of death, AIDS-defining event or non-AIDS defining event. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit. Only new events were considered, an event that was also reported at or prior to study entry was not included. If a participant experienced multiple events, then the time of the first event was used in the analysis. AIDS defining events included parasitic, fungal, bacterial, and viral infections as well as neoplastic diseases, and neurological disorders. Non-AIDS defining events included malignancies, diabetes, neuropathies, cardiac and renal events.'}, {'measure': 'Time From Study Entry/Randomization to the First of Death or Hospitalization [CPI+SOC v SOC]', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Event time was the exact week of death or hospitalization. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit. If a participant experienced multiple events, then the time of the first event was used in the analysis.'}, {'measure': 'Percent of Participants With Death or Hospitalization by Week 48 [CPI+SOC v SOC]', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Event time was the exact week of death or hospitalization. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit. If a participant experienced multiple events, then the time of the first event was used in the analysis.'}, {'measure': 'Time From Study Entry/Randomization to Treatment Modification or Discontinuation [CPI+SOC v SOC]', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Treatment modification is defined as the first occurrence of a substitution or subtraction of one or more drugs in the study regimen, a temporary hold lasting 7 days or longer, or the addition of a new drug to the regimen. This would not include splitting any fixed dose combination medications if the participant continues on the active drugs of the combination. Event time was the exact week of the modification or discontinuation. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit.'}, {'measure': 'Percent of Participants With Treatment Modification or Discontinuation by Week 48 [CPI+SOC v SOC]', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Treatment modification is defined as the first occurrence of a substitution or subtraction of one or more drugs in the study regimen, a temporary hold lasting 7 days or longer, or the addition of a new drug to the regimen. This would not include splitting any fixed dose combination medications if the participant continues on the active drugs of the combination. Event time was the exact week of the modification or discontinuation. Censoring time was the earliest time point between last dose week and the week of the last step 1/2 visit.'}, {'measure': 'Time From Study Entry/Randomization to Treatment Modification or Discontinuation Due to Toxicity [CPI+SOC v SOC]', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Treatment modification is defined as the first occurrence of a substitution or subtraction of one or more drugs in the study regimen, a temporary hold lasting 7 days or longer, or the addition of a new drug to the regimen, due to an adverse event. This would not include splitting any fixed dose combination medications if the participant continues on the active drugs of the combination. Event time was the exact week of the modification or discontinuation. Censoring time was the earliest time point between last dose week and the week of the last step 1/2 visit. DAIDS AE Grading Table, Version 1.0 was used.'}, {'measure': 'Percent of Participants With Treatment Modification or Discontinuation Due to Toxicity by Week 48 [CPI+SOC v SOC]', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Treatment modification is defined as the first occurrence of a substitution or subtraction of one or more drugs in the study regimen, a temporary hold lasting 7 days or longer, or the addition of a new drug to the regimen, due to an adverse event. This would not include splitting any fixed dose combination medications if the participant continues on the active drugs of the combination. Event time was the exact week of the modification or discontinuation. Censoring time was the earliest time point between last dose week and the week of the last step 1/2 visit. DAIDS AE Grading Table, Version 1.0 was used.'}, {'measure': 'Time From Study Entry/Randomization to the Development of Immune Reconstitution Inflammatory Syndrome (IRIS) [CPI+SOC v SOC]', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Event time was the exact week of the diagnosis. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit.'}, {'measure': 'Percent of Participants That Developed Immune Reconstitution Inflammatory Syndrome (IRIS) by Week 48 [CPI+SOC v SOC]', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Event time was the exact week of the diagnosis. Censoring time was the earlier of last contact week and the week of the last step 1/2 visit.'}, {'measure': 'Time to First Dose Modification Due to Grade 3 or 4 Toxicity [CPI+SOC v SOC]', 'timeFrame': 'From study entry through Step 1/2 follow-up; median (IQR) step 1/2 follow-up was 72 (72,108) weeks', 'description': 'Event time was the exact week of the modification. Censoring time was the earliest time point between last dose week and the week of the last step 1/2 visit. DAIDS AE Grading Table, Version 1.0 was used.'}, {'measure': 'Percent of Participants With a Dose Modification Due to Grade 3 or 4 Toxicity by Week 48 [CPI+SOC v SOC]', 'timeFrame': 'From study entry to Week 48', 'description': 'Results report percent of participants reaching outcome by week 48 using Kaplan-Meier method. Event time was the exact week of the modification. Censoring time was the earliest time point between last dose week and the week of the last step 1/2 visit. DAIDS AE Grading Table, Version 1.0 was used.'}, {'measure': 'Change From Baseline in CD4+ T-cell Count [CPI+SOC v SOC]', 'timeFrame': 'Baseline, week 24, 48, and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen.'}, {'measure': 'Change From Baseline in Fasting Values of Total Cholesterol [CPI+SOC v SOC]', 'timeFrame': 'Baseline, week 24, 48, and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen.'}, {'measure': 'Change From Baseline in Fasting Values of High-density Lipoprotein Cholesterol [CPI+SOC v SOC]', 'timeFrame': 'Baseline, week 24, 48, and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen.'}, {'measure': 'Change From Baseline in Fasting Values of Calculated Low-density Lipoprotein Cholesterol [CPI+SOC v SOC]', 'timeFrame': 'Baseline, week 24, 48, and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen.'}, {'measure': 'Change From Baseline in Fasting Values of Triglycerides [CPI+SOC v SOC]', 'timeFrame': 'Baseline, week 24, 48, and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen.'}, {'measure': 'Change From Baseline in Fasting Values of Glucose [CPI+SOC v SOC]', 'timeFrame': 'Baseline, week 24, 48, and 72', 'description': 'Baseline is defined as the last measurement obtained on or before the earlier of the following two dates: the date of entry/randomization plus three days (this is the time allowed in the protocol for starting study-defined ART) and the date of starting the study-defined ARV regimen.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'conditions': ['HIV-1 Infection']}, 'referencesModule': {'references': [{'pmid': '36039892', 'type': 'DERIVED', 'citation': 'Avihingsanon A, Hughes MD, Salata R, Godfrey C, McCarthy C, Mugyenyi P, Hogg E, Gross R, Cardoso SW, Bukuru A, Makanga M, Badal-Aesen S, Mave V, Ndege BW, Fontain SN, Samaneka W, Secours R, Van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Munyanga C, Chagomerana M, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC, Grinsztejn B; A5288 Study team. Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial. J Int AIDS Soc. 2022 Jun;25(6):e25905. doi: 10.1002/jia2.25905.'}, {'pmid': '32049773', 'type': 'DERIVED', 'citation': 'Godfrey C, Hughes MD, Ritz J, Coelho L, Gross R, Salata R, Mngqibisa R, Wallis CL, Mumbi ME, Matoga M, Poongulali S, Van Schalkwyk M, Hogg E, Fletcher CV, Grinsztejn B, Collier AC; A5288 team. Brief Report: Sex Differences in Outcomes for Individuals Presenting for Third-Line Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2020 Jun 1;84(2):203-207. doi: 10.1097/QAI.0000000000002324.'}, {'pmid': '31528850', 'type': 'DERIVED', 'citation': 'Gross R, Ritz J, Hughes MD, Salata R, Mugyenyi P, Hogg E, Wieclaw L, Godfrey C, Wallis CL, Mellors JW, Mudhune VO, Badal-Faesen S, Grinsztejn B, Collier AC. Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial. Lancet Digit Health. 2019 May;1(1):e26-e34. doi: 10.1016/S2589-7500(19)30006-8. Epub 2019 May 6.'}, {'pmid': '31371262', 'type': 'DERIVED', 'citation': 'Grinsztejn B, Hughes MD, Ritz J, Salata R, Mugyenyi P, Hogg E, Wieclaw L, Gross R, Godfrey C, Cardoso SW, Bukuru A, Makanga M, Faesen S, Mave V, Wangari Ndege B, Nerette Fontain S, Samaneka W, Secours R, van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Avihingsanon A, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC; A5288 Team. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. Lancet HIV. 2019 Sep;6(9):e588-e600. doi: 10.1016/S2352-3018(19)30146-8. Epub 2019 Jul 29.'}], 'seeAlsoLinks': [{'url': 'https://rsc.tech-res.com/docs/default-source/safety/table_for_grading_severity_of_adult_pediatric_adverse_events.pdf?sfvrsn=6', 'label': 'DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December 2004; Clarification, August 2009'}, {'url': 'https://rsc.tech-res.com/docs/default-source/safety/manual_for_expedited_reporting_aes_to_daids_v2.pdf?sfvrsn=10', 'label': 'Manual for Expedited Reporting of Adverse Events to DAIDS (DAIDS EAE Manual), Version 2.0, January 2010'}]}, 'descriptionModule': {'briefSummary': "The study was done to:\n\n* test a strategy of using a resistance test to choose anti-HIV drugs\n* see how well combinations of new anti-HIV drugs work to lower HIV infection\n* see if taking new anti-HIV drugs together is safe and tolerable\n* see if text messages improve people's anti-HIV drug-taking behavior (only at sites participating in the adherence study)\n* in people taking certain combinations of anti-HIV drugs with an anti-TB drug, compare how these drugs act in the body\n* to see how people do after they stop having frequent clinic visits as part of a research study", 'detailedDescription': "A5288 was an open-label phase IV, prospective interventional, strategy study in resource-limited settings (RLS) for HIV-1 infected participants with triple-class experience or resistance to nucleoside reverse transcriptase inhibitors (NRTIs), non-NRTIs (NNRTIs), and protease inhibitors (PIs) and who were failing their current regimen. The use of novel agents and contemporary clinical decision management tools that include standard genotyping and plasma HIV viral load (VL) monitoring were evaluated. The screening genotype results and antiretroviral (ARV) history were used to allocate potential participants to one of four Cohorts (A, B, C or D) and to select an associated ARV regimen based on the Cohort assignment. In brief, individuals assigned to Cohort A continued on the same PI as in their second-line regimen, with the ability to modify NRTIs. Those assigned to Cohort B who were negative for hepatitis B were randomized to receive RAL and DRV/RTV with either the best available NRTIs (Cohort B1) or ETR (Cohort B2). If they were positive for hepatitis B they were assigned to Cohort B3 and received RAL, DRV/RTV and either FTC/TDF or 3TC/TDF. Individuals assigned to Cohort C received RAL and DRV/RTV with the best available NRTIs. Those ineligible for Cohorts A, B or C were assigned to Cohort D and received the best available regimen that included study provided drugs and any locally provided drugs.\n\nAt sites where feasible and relevant, the study evaluated an adherence support intervention. This involved a randomized comparison of a cell phone-based adherence support intervention plus local standard-of-care adherence support procedures (CPI+SOC) versus the SOC adherence support procedures.\n\nParticipants enrolled to the study in Step 1. If a participant experienced a confirmed virologic failure (defined as two consecutive HIV-1 RNA measures \\>= 1000 copies/mL) at/after 22 weeks on their Step 1 regimen, they had another genotype test performed and cohort/regimen selected for Step 2. With the exception of one additional visit 4 weeks after enrollment to Step 2, the visit schedule for Step 2 followed the participant's original Step 1 schedule throughout the remainder of follow up.\n\nParticipants were followed in Steps 1 and 2 until 48 weeks after the last participant was enrolled to Step 1. During the first 48 weeks after Step 1 enrollment, clinic visits occurred at weeks 4, 12, 24, 36 and 48. After week 48, visits occurred every 12 weeks for adherence, safety and efficacy measures.\n\nParticipants had a final step 1/2 visit between November 22, 2016 and February 13, 2017. At the final step 1/2 visit, participants taking RAL, ETR, or DRV who were unable to obtain these drugs locally (e.g., through local treatment programs), and were otherwise eligible, entered Step 3 and continued to receive these drugs through the study for up to 96 additional weeks. Step 3 participants were dispensed ARVs every 12 weeks and had clinical assessments every 24 weeks. The purpose of Step 3 was to assist participants with the transition back to local care.\n\nThe primary analysis specified in the protocol and in the Statistical Analysis Plan was to estimate the proportion of participants in the overall study population who were virologically suppressed (HIV-1 RNA ≤200 copies/mL) at week 48 with a 95% confidence interval."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria for Step 1:\n\n* HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA VL.\n* Any previous combination of ARV treatment at any time with at least one regimen that contained one NNRTI and two NRTIs which was replaced with a PI-based regimen because of virologic, immunologic, or clinical treatment failure, or because of toxicity.\n\nNOTE: All potential participants with prior RAL exposure were assigned to either Cohort A or Cohort D.\n\n* At screening, receipt of a PI-based regimen with no regimen change for a minimum of 24 weeks prior to screening.\n* Confirmation of VF of current second-line PI-based ART. NOTE A: Failure of the current second-line regimen was defined as two consecutive measurements of plasma HIV-1 RNA ≥1000 copies/mL obtained at least 1 day apart while on the current PI-based regimen. "Current PI-based regimen" and "current regimen" were understood to be the regimen described (ie, the regimen that the candidate was taking when the first VF sample was drawn plus only those modifications allowed).\n* CD4+ T-cell count result from a specimen drawn within 103 days prior to study entry\n* Laboratory values obtained within 30 days prior to study entry:\n\n * Absolute neutrophil count (ANC) ≥ 500/mm\\^3\n * Hemoglobin ≥7.5 g/dL\n * Platelet count ≥40,000/mm\\^3\n * Creatinine ≤2 X upper limit of normal (ULN)\n * Aspartate aminotransferase (AST), serum glutamic oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT), serum glutamic pyruvic transaminase (SGPT), and alkaline phosphatase ≤5 x ULN\n * Total bilirubin ≤2.5 x ULN\n * Creatinine clearance (CrCl) \\>30 mL/min, either measured or estimated by Cockcroft-Gault equation\n * Hepatitis B panel that includes HbsAB, HBcAB, and HBsAG or only HBsAG, with plasma stored for later anti-HBs and anti-HBc.\n\nNOTE A: Candidates who were eligible for cohort B and who were positive for active hepatitis B infection were assigned to sub-cohort B3 at registration/randomization.\n\nNOTE B: Candidates with CrCl \\<60 mL/min who were also positive for active hepatitis B infection were not eligible.\n\n* Females of reproductive potential (women who have not been post-menopausal for at least 24 consecutive months, ie, who have had menses within the preceding 24 months, or women who have not undergone surgical sterilization, hysterectomy or bilateral salpingectomy or bilateral oophorectomy or tubal ligation) must have had a negative serum or urine pregnancy test prior to the submission of the screening genotype testing sample and again within 48 hours prior to randomization or registration.\n* Female participants of reproductive potential must have agreed not to participate in the conception process (ie, active attempt to become pregnant, in vitro fertilization), and if participating in sexual activity that could lead to pregnancy, the female participant must have used at least one reliable form of contraceptive. Female participants must have continued to use contraceptives while receiving study treatment and for 6 weeks after stopping study treatment.\n\nAcceptable forms of contraceptives included:\n\n* Condoms (male or female) with or without a spermicidal agent\n* Diaphragm or cervical cap with spermicide\n* Intrauterine device (IUD)\n* Hormonal contraception\n\nFemale participants who were not of reproductive potential or whose male partner(s) had documented azoospermia) were not required to use contraceptives. Any statement of self-reported sterility or that of her partner\'s must have been entered in the source documents.\n\nNOTE: Acceptable documentation of lack of reproductive potential was oral or written documentation from the participant.\n\n* Karnofsky performance score \\>/= 70 within 30 days prior to study entry.\n* Ability and willingness of potential participant to provide informed consent.\n* Willingness of potential participant to adhere to protocol requirements, especially with respect to treatment assignment and ability to obtain non-study provided ART, if needed.\n* Ability to take oral study medications.\n* No intention of permanent relocation that would preclude attending Step 1 and 2 study follow-up visits.\n* Availability of a successful, interpretable resistance genotype report from a DAIDS-approved regional genotyping facility from testing performed on a plasma sample that was collected during screening (ie, at or after the date that a sample is collected to confirm HIV-1 virologic failure) and which was shipped to a regional resistance testing laboratory once documentation of two screening plasma HIV-1 RNA values ≥1000 copies/mL were available.\n* Identification of a cohort assignment and ARV regimen for use on study, selected from the recommended options provided by the site investigator, and reviewed and approved by the A5288 Clinical Management Committee (CMC).\n\nExclusion Criteria for Step 1:\n\n* Pregnancy or breast-feeding.\n* Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulation.\n* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would have interfered with adherence to study requirements.\n* Serious illness requiring systemic treatment and/or hospitalization until candidate either completes therapy or was clinically stable on therapy, in the opinion of the site investigator, for at least 7 days prior to study entry.\n* Concurrent illness or condition that would compromise the ability to take study medication, follow the protocol, or that would make participation not in the best interest of the participant, per the site investigator.\n* Requirement for taking any of the prohibited medications with the selected ARV study regimen, or within 14 days prior to study entry.\n\nNOTE: Study candidates should not have discontinued any component of their ART during screening. The 14-day restriction on prohibited medications did not apply to ARVs.\n\n* Active tuberculosis (TB) or rifampin exposure less than 2 weeks prior to study entry.\n* Any exposure to darunavir or etravirine.'}, 'identificationModule': {'nctId': 'NCT01641367', 'acronym': 'MULTI-OCTAVE', 'briefTitle': 'A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure', 'organization': {'class': 'NETWORK', 'fullName': 'Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections'}, 'officialTitle': 'Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure (MULTI-OCTAVE)', 'orgStudyIdInfo': {'id': 'ACTG A5288'}, 'secondaryIdInfos': [{'id': '1U01AI068636', 'link': 'https://reporter.nih.gov/quickSearch/1U01AI068636', 'type': 'NIH'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Cohort A', 'description': 'Under Protocol version 1.0:\n\nNo resistance to NRTIs, PIs, or NNRTI\n\n• Continue current second-line regimen; NRTIs could be modified\n\nChanged under LOA#2 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue second-line regimen which may include LPV/RTV; NRTIs could be modified\n\nChanged under LOA#3 to:\n\nNo LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure\n\n• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued.', 'interventionNames': ['Drug: Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)', 'Other: SOC adherence versus SOC+CPI adherence']}, {'type': 'EXPERIMENTAL', 'label': 'Sub-cohort B1', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening\n\n• Best available NRTIs, RAL, \\& DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• Best available NRTIs, RAL, \\& DRV/RTV', 'interventionNames': ['Drug: Darunavir', 'Drug: Raltegravir', 'Other: SOC adherence versus SOC+CPI adherence']}, {'type': 'EXPERIMENTAL', 'label': 'Sub-cohort B2', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening\n\n• ETR, RAL, and DRV/RTV\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)\n\n• ETR, RAL, and DRV/RTV', 'interventionNames': ['Drug: Darunavir', 'Drug: Etravirine', 'Drug: Raltegravir', 'Other: SOC adherence versus SOC+CPI adherence']}, {'type': 'EXPERIMENTAL', 'label': 'Sub-cohort B3', 'description': 'Under Protocol version 1.0:\n\nSusceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC\n\nChanged under LOA#2 to:\n\nResistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)\n\n• RAL, DRV/RTV, and FTC/TDF or TDF+3TC', 'interventionNames': ['Drug: Darunavir', 'Drug: Emtricitabine/tenofovir disoproxil fumarate', 'Drug: Raltegravir', 'Other: SOC adherence versus SOC+CPI adherence']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort C', 'description': 'Under Protocol version 1.0:\n\nResistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV)\n\n• Best available NRTIs, RAL, and DRV/RTV\n\nChanged under LOA#2:\n\nResistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure\n\n• Best available NRTIs, RAL, and DRV/RTV', 'interventionNames': ['Drug: Darunavir', 'Drug: Raltegravir', 'Other: SOC adherence versus SOC+CPI adherence']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort D', 'description': 'Under Protocol version 1.0:\n\nMultiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nChanged under LOA#2:\n\nNot eligible for Cohort A, B, or C:\n\n• Best available regimen, including study-provided and any locally available drugs\n\nUpdated under protocol v2.0:\n\n• Best available ART regimen, including study-provided and any locally available non-experimental drugs', 'interventionNames': ['Drug: Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available', 'Other: SOC adherence versus SOC+CPI adherence']}], 'interventions': [{'name': 'Darunavir', 'type': 'DRUG', 'otherNames': ['DRV', 'Prezista'], 'description': 'Participants were administered darunavir orally as one 600 mg tablet twice a day (1200 mg per day) with food (taken with Ritonavir 100 mg twice a day \\[200 mg per day\\])', 'armGroupLabels': ['Cohort C', 'Sub-cohort B1', 'Sub-cohort B2', 'Sub-cohort B3']}, {'name': 'Etravirine', 'type': 'DRUG', 'otherNames': ['ETR', 'Intelence'], 'description': 'Patients were administered Etravirine orally as two 100 mg tablets or one 200 mg tablet twice a day (400 mg per day) following a meal.', 'armGroupLabels': ['Sub-cohort B2']}, {'name': 'Emtricitabine/tenofovir disoproxil fumarate', 'type': 'DRUG', 'otherNames': ['FTC/TDF', 'Truvada'], 'description': 'Patients were administered FTC/TDF orally as one fixed dose combination tablet (FTC 200 mg/TDF 300 mg) once daily, with or without food.', 'armGroupLabels': ['Sub-cohort B3']}, {'name': 'Raltegravir', 'type': 'DRUG', 'otherNames': ['RAL', 'Isentress'], 'description': 'Participants were administered Raltegravir orally as one 400 mg tablet twice daily (800 mg per day), with or without food', 'armGroupLabels': ['Cohort C', 'Sub-cohort B1', 'Sub-cohort B2', 'Sub-cohort B3']}, {'name': 'Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)', 'type': 'DRUG', 'description': 'LPV/r and ATV/r were the preferred bPIs for second-line ART. TDF + (3TC or FTC) or AZT + 3TC were the most frequent NRTI backbones. Cohort A did not include any of the new drugs; therefore, it is distinct from Cohorts B, C, and D.', 'armGroupLabels': ['Cohort A']}, {'name': 'Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available', 'type': 'DRUG', 'description': 'For Cohort D, in many situations a participant received the same regimen that patients are getting in Cohorts B and C if that was the best combination that can be obtained according to his/her resistance profile and drug availability (as for many countries there were no further drug options beyond the available study drugs).', 'armGroupLabels': ['Cohort D']}, {'name': 'SOC adherence versus SOC+CPI adherence', 'type': 'OTHER', 'description': '* not participating in the adherence randomization; OR\n* randomized to SOC adherence; OR\n* randomized to SOC+CPI adherence.', 'armGroupLabels': ['Cohort A', 'Cohort C', 'Cohort D', 'Sub-cohort B1', 'Sub-cohort B2', 'Sub-cohort B3']}]}, 'contactsLocationsModule': {'locations': [{'zip': '9043010', 'city': 'Porto Alegre', 'state': 'Rio Grande do Sul', 'country': 'Brazil', 'facility': 'Hospital Nossa Senhora da Conceicao CRS (12201)', 'geoPoint': {'lat': -30.03283, 'lon': -51.23019}}, {'zip': '21045', 'city': 'Rio de Janeiro', 'country': 'Brazil', 'facility': 'Instituto de Pesquisa Clinica Evandro Chagas (12101)', 'geoPoint': {'lat': -22.90642, 'lon': -43.18223}}, {'zip': 'HT-6110', 'city': 'Port-au-Prince', 'state': 'Bicentaire', 'country': 'Haiti', 'facility': 'Les Centres GHESKIO CRS (30022)', 'geoPoint': {'lat': 18.54349, 'lon': -72.33881}}, {'city': 'Port-au-Prince', 'country': 'Haiti', 'facility': 'GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS', 'geoPoint': {'lat': 18.54349, 'lon': -72.33881}}, {'zip': '411001', 'city': 'Pune', 'state': 'Maharashtra', 'country': 'India', 'facility': 'BJ Medical College CRS (31441)', 'geoPoint': {'lat': 18.51957, 'lon': 73.85535}}, {'zip': '600113', 'city': 'Chennai', 'state': 'Taramani', 'country': 'India', 'facility': 'Chennai Antiviral Research and Treatment (CART) CRS (11701)', 'geoPoint': {'lat': 13.08784, 'lon': 80.27847}}, {'zip': '30100', 'city': 'Eldoret', 'country': 'Kenya', 'facility': 'AMPATH at Moi Univ. Teaching Hosp. Eldoret CRS (12601)', 'geoPoint': {'lat': 0.52036, 'lon': 35.26993}}, {'zip': '40100', 'city': 'Kisumu', 'country': 'Kenya', 'facility': 'Kenya Medical Research Institute/Center for Disease Control (KEMRI/CDC) CRS (31460)', 'geoPoint': {'lat': -0.10221, 'lon': 34.76171}}, {'city': 'Lilongwe', 'country': 'Malawi', 'facility': 'Malawi CRS (12001)', 'geoPoint': {'lat': -13.96692, 'lon': 33.78725}}, {'city': 'San Miguel', 'state': 'Lima region', 'country': 'Peru', 'facility': 'San Miguel CRS (11302)', 'geoPoint': {'lat': -11.45222, 'lon': -76.62528}}, {'zip': '18 PE', 'city': 'Lima', 'country': 'Peru', 'facility': 'Barranco CRS (11301)', 'geoPoint': {'lat': -12.04318, 'lon': -77.02824}}, {'zip': '2193', 'city': 'Johannesburg', 'state': 'Gauteng', 'country': 'South Africa', 'facility': 'University of the Witwatersrand Helen Joseph (WITS HJH) CRS (11101)', 'geoPoint': {'lat': -26.20227, 'lon': 28.04363}}, {'zip': '7505', 'city': 'Cape Town', 'state': 'West Cape', 'country': 'South Africa', 'facility': 'Family Clinical Research Unit (FAM-CUR) CRS (8950)', 'geoPoint': {'lat': -33.92584, 'lon': 18.42322}}, {'zip': '4013 SF', 'city': 'Durban', 'country': 'South Africa', 'facility': 'Durban Adult HIV CRS (11201)', 'geoPoint': {'lat': -29.8579, 'lon': 31.0292}}, {'city': 'Johannesburg', 'country': 'South Africa', 'facility': 'Soweto ACTG CRS (12301)', 'geoPoint': {'lat': -26.20227, 'lon': 28.04363}}, {'zip': '10330', 'city': 'Bangkok', 'state': 'Patumwan', 'country': 'Thailand', 'facility': '31802 Thai Red Cross AIDS Research Centre (TRC-ARC) CRS', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}, {'zip': '50200', 'city': 'Chiang Mai', 'country': 'Thailand', 'facility': '31784 Chiang Mai University HIV Treatment CRS', 'geoPoint': {'lat': 18.79038, 'lon': 98.98468}}, {'city': 'Kampala', 'country': 'Uganda', 'facility': 'JCRC CRS', 'geoPoint': {'lat': 0.31628, 'lon': 32.58219}}, {'city': 'Harare', 'country': 'Zimbabwe', 'facility': 'UZ-Parirenyatwa CRS (30313)', 'geoPoint': {'lat': -17.82772, 'lon': 31.05337}}], 'overallOfficials': [{'name': 'Beatriz Grinsztejn, MD, PhD', 'role': 'STUDY_CHAIR', 'affiliation': 'Instituto de Pesquisa Clinica Evandro Chagas-Fiocruz'}, {'name': 'Peter Mugyenyi, MB ChB, FRCP, DSc', 'role': 'STUDY_CHAIR', 'affiliation': 'Joint Clinical Research Center'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections', 'class': 'NETWORK'}, 'collaborators': [{'name': 'National Institute of Allergy and Infectious Diseases (NIAID)', 'class': 'NIH'}, {'name': 'AbbVie', 'class': 'INDUSTRY'}, {'name': 'Gilead Sciences', 'class': 'INDUSTRY'}, {'name': 'Janssen Pharmaceuticals', 'class': 'INDUSTRY'}, {'name': 'Merck Sharp & Dohme LLC', 'class': 'INDUSTRY'}, {'name': 'Dimagi Inc.', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}